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ABSTRACT 
 
Childhood is a critical time of growth, and decisions made during this time 
lead to positive and negative health consequences, specifically pertaining to 
adiposity.  There is convincing evidence that children who are overweight and 
obese are at higher risk for adult obesity and risk factors associated with obesity 
for their whole life course.  Puberty is a critical time of adipose tissue expansion, 
and it is accepted by most that this is the age where the number of adipocytes is 
set for adulthood.  Further it is believed that before puberty, adipose tissue 
expands by hyperplasia, while after puberty, adipose tissue expands by 
hypertrophy.  The time leading up to puberty represents a critical time. Yet, little 
is known about the interaction between age, physical activity, and adipose tissue 
expansion in young, growing animals.  Thus, I employed a unique model of 
childhood obesity to test whether: 1) seven days of decreased physical activity 
(wheel lock) in 49-56 day old rats and 70-77 day old rats would result in gains in 
visceral adipose mass seen in age-matched sedentary rats concurrent with an 
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increase in adipocyte size and inflammatory mRNA expression (Chapter 2), and 
2) glucocorticoid block would attenuate the visceral adipose depot gains seen 
with wheel lock in rats at sexual maturity (Chapter 3).   Here, I present evidence 
that the age at which wheel lock occurs influences visceral adipose tissue growth 
and propose a mechanism for this growth at two ages of pre-pubertal growth (49-
56 days of age and 70-77 days of age).  Specifically, rats that undergo wheel 
lock for 7 days at 49-56 days of age show no differences in total body mass, 
mean adipocyte diameter, or mass of omental, epididymal, and perirenal adipose 
tissue depots compared to rats that remained physically active.  However, rats 
that undergo wheel lock for 7 days at 70-77 days of age have an increased rate 
of body mass, fat mass, and % body fat gained and have increased depot mass 
and total number of adipocytes in epididymal and perirenal adipose tissue, 
resulting in epididymal and perirenal expansion via hyperplasia.  This expansion 
occurs without an inflammatory component.  Further, I present evidence that 
glucocorticoids play a role in visceral adipose expansion during wheel lock.  
Blocking glucocorticoid action attenuated rapid growth of adipose tissue mass 
(catch-up fat) that occurred during wheel lock at the same level that maintaining 
voluntary wheel running does, but importantly it does not exhibit the same 
transcript expression as running.  Collectively, these findings reinforce the role of 
the beneficial effects of physical activity.  Sustained daily physical activity in 
young animals maintains lower body fat %, lowers visceral adiposity and total 
adipocyte number, which can be translated into a powerful public health 
message of primary prevention of obesity.  
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CHAPTER 1 
 
Introduction 
 
Physical inactivity is connected to the obesity crisis facing children and 
adolescents in the United States (U.S.) [1-3].  There is an increased prevalence 
of physical inactivity that occurs as children age to adolescents in the U.S. [1, 3] 
along with an increased portion of children who are obese [4].  Moreover, puberty 
is a critical time of adipose tissue expansion [5] where the number of adulthood 
adipocytes is generally set [6].  Fewer whole-body adipocytes and less fat mass 
accumulation during childhood is correlated with a decrease risk of obesity and 
all of the accompanying obesity-related problems later in life [7].  It is clear that 
decisions made early in life have major health effects later in life.  Taken 
together, we see an earlier onset of obesity and an increase in physical inactivity 
in children occurring at a critical time of adipose tissue growth.  Given these 
facts, animal models that allow the study of adipose tissue plasticity within the 
abdominal cavity in an inactivity context are valuable to gain an understanding of 
the potential negative consequences of early childhood inactivity and on fat gain.  
Preforming studies that obtain visceral fat biopsies from healthy and unhealthy 
children is unethical, so animal models are required to obtain medical information 
for the health of children.  Our laboratory has a unique model that is effective at 
investigating this, and was the model of choice for the two studies presented in 
this dissertation [8]. The overlying theme of this dissertation is how decreased 
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physical activity affects adipose tissue in a rodent model of childhood 
obesity.Rats are a good model for children in regards to studying adipose tissue 
for the following reasons:  1) rats gain body mass (first 11 weeks of life) in 
parallel with gains for children (first 20 years of life) 
[http://www.cdc.gov/growthcharts/clinical_charts.htm and [9]], 2) the number of 
adipocytes in rats dramatically increases in pre-pubescent years and then 
plateaus thereafter just as is observed in humans [6, 10], and 3) in rats, we are 
able to have access to all tissue for molecular investigation [8].  For these 
reasons, young, Wistar rats were selected for the two studies presented in this 
dissertation.   
The Booth Laboratory Wheel Lock (WL) Model is a unique, effective way 
of studying the effects of a sudden decrease in physical activity in the context of 
children and adolescents [8], and is described in detail in Chapter 2 and Chapter 
3.  An example of this paradigm is children ending a summer of play to sit in 
school is a human example of decreased activity.  It is important to note that the 
WL model is very novel, and few studies have been performed using a WL 
model, but that does not mean WL is irrelevant.  Rather, I would argue that WL is 
a highly human-relevant, yet still underappreciated, model of human behavior, 
which provides another model to study decreased activity at a molecular level.    
Adipose tissue is an endocrine organ  
Adipose tissue was once thought of as a passive tissue functioning solely 
to store excess triglycerides.  This view is now universally rejected due to a 
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plethora of evidence showing the diverse metabolic activity of adipose [11].  
Adipose tissue can generally be classified as either white adipose tissue (WAT) 
or brown adipose tissue (BAT).  BAT is characterized by expression of 
uncoupling protein-1 (UCP-1) and is considered a depot more metabolically 
active and is specialized for heat production [12].  Recent literature suggests a 
cross-over type of fat called BRITE (BRown-whITE) or beige fat, which is 
characterized by a white adipocyte that can express UCP-1 [13, 14].  WAT 
makes up the majority of adipose tissue in humans and rodents, and is the 
predominant type of adipose tissue in mammals [11, 15] and is the focus of this 
dissertation.   
Adipocytes make up the majority of adipose tissue volume, but there are 
many other multipotent cell types in adipose tissue, referred to as the stromal 
cells.  Cells in the stromal fraction have the capacity to differentiate into 
adipocytes, chondrocytes, and osteoblasts, as well as secrete cytokines and 
growth factors (referred to as adipokines) with autocrine, paracrine, and 
endocrine functions [16].  Due to the large size of whole-body adipose tissue and 
the extensive vascularization, adipose tissue has the ability to release vast 
quantities of adipokines into the systemic circulation and significantly affect body 
functions [17].  It has been suggested that adipose tissue is the source of many 
of the inflammatory markers that are responsible for the increase in circulating 
pro-inflammatory cytokines [18].  With increased obesity and an increase in 
adipocyte size, there is an adipose tissue phenotype shift from an anti-
inflammatory immune environment to a pro-inflammatory immune environment 
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that is concurrent with the development of metabolic complications like insulin 
resistance and type 2 diabetes [19].  Specifically, there is a chronic state of low-
grade inflammation, [20] an increase in circulating pro-inflammatory cytokines 
including TNF, IL-6, and monocyte chemotactic protein-1 (MCP-1) [21], and a 
decrease in anti-inflammatory cytokines like IL-10.   
 
FIGURE 1: DXA scans comparing gynoid and android adiposity.  Gynoid or hip 
and thigh adiposity at left versus android or central adiposity at right (images 
from: [[22] and gehealthcare.com].  Waist and hip are outlined with a red box.  
Andriod adiposity, especially when the adipose tissue is located in the viscera, 
poses the highest risk for health problems. Note in gyonid adiposity (left) the 
smaller waist and larger hip, while in android adiposity (right) the larger waist and 
smaller hip.  
 
Location of adipose tissue within the body is heterogeneous with different 
depots exerting a variety of functions [23].   While subcutaneous AT (SAT), often 
distributed in the hip and thigh area is considered “protective fat depot” [24, 25], 
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central adiposity, especially visceral adipose tissue (VAT), is implicated in 
metabolic and chronic inflammatory disorders [23] and is considered to be 
potentially pathogenic and predisposes people to higher risk of disease than 
other depots [26-34].  Therefore central, abdominal obesity, referred to as 
android adiposity, is considered a risk factor for metabolic syndrome, while 
peripheral, hip and thigh obesity, which is referred to as gynoid obesity, is not 
(Figure 1).    
It has previously been reported that there are metabolic differences 
between subcutaneous and VAT and even between different VAT depots [35]. 
Despite the differences, results from the Framingham Heart Study, which 
investigated 3001 healthy adults, found that SAT and VAT were positively 
associated with hypertension, triglycerides, HDL cholesterol, and insulin 
resistance [24], suggesting that increased adiposity, no matter the location, puts 
people at higher risk for disease.  Still the authors of the Framingham Heart 
Study found that VAT is more highly correlated with metabolic syndrome than 
SAT.  Two main reasons that VAT is considered to be “unhealthy” is 1) the close 
proximity to the liver and 2) the inherent damaging molecular characteristics [30].   
A proposed mechanism by which VAT exerts harmful metabolic effects is that 
there is an enhanced efflux of inflammatory cytokines and free fatty acids through 
the portal vein to the liver [36].  Omental (OMAT) is VAT most commonly cited in 
human studies, while epididymal (EAT) and perirenal (PRAT) depots are 
commonly investigated in rodent studies.  As will be presented later, OMAT 
responds differently to treatments than EAT and PRAT.  VAT, specifically OMAT, 
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EAT, and PRAT adipose tissue depots were investigated in this dissertation due 
to their highly plastic nature as well as their positive correlation to metabolic risk.  
                              
Adipose tissue expands by hypertrophy or hyperplasia 
AT is highly plastic and can rapidly change based on animals 
physiological and pathophysiological status [37-40].  Adipose tissue can expand 
by either hypertrophy (increase in the size of an adipocyte) or hyperplasia 
(increase in the number of adipocytes) (Figure 2).  
 
FIGURE 2.  Two mechanisms by which adipose tissue can expand.  
Hyperplasic expansion originates from preadipocyte differentiation and expands 
adipose tissue by adding more adipocytes.  Hypertrophic expansion involves in 
increased lipid storage in existing adipocytes and expands adipose tissue by 
making already-existing adipocytes larger.  Figure was modified from [41]  
 
Hyperplasia results from stem cell recruitment and differentiation into new, 
small adipocytes and a consequent increase in total adipocyte number in a given 
depot [42], and is generally a “healthy” adipose tissue adaptation due to 
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maintenance of smaller adipocytes [43].  The stromal fraction of adipose tissue 
contains pluripotent mesenchymal stem cells (MSCs) that can undergo 
commitment and differentiation into adipocytes, myocytes, chondrocytes, and 
osteocytes [44-47].  MSCs are recruited to the adipocyte lineage by excessive 
energy intake in vivo [48], which induce MSCs towards preadipocyte hyperplasia 
and differentiation into the adipocyte phenotype and enlargement of mature 
adipocoytes [49].  Figure 3 illustrates many of the known markers of the process 
from MSC to mature adipocyte.  
As mentioned previously, childhood, specifically puberty, is a critical time 
of adipose tissue expansion [5], and it is currently accepted by the majority of 
scientists who study adipose tissue, that the number of adulthood adipocytes is 
generally set during this time [6, 50, 51].  Smaller adipocytes are considered to 
be healthier [52], and as a result, adipose tissue expansion via hyperplasia 
results in a healthier phenotype than adipose tissue expansion via hypertrophy 
[53] even in the presence of obesity [54].  This evidence suggests that one of the 
keys to avoiding these metabolic complications is to maintain healthy adipose 
tissue (i.e. small adipocytes and an anti-inflammatory environment.   
Hypertrophy involves increased lipid storage in pre-existing adipocytes 
and a resultant need for adipose tissue remodeling to accommodate the larger 
adipocytes, which often is accompanied by an inflammatory process [55].  
Therefore, it is believed that adipose tissue expansion by hypertrophy, especially 
VAT expansion via hypertrophy, leads to an unhealthy phenotype that is 
concurrent with the development of metabolic complications and is a risk factor 
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for type 2 diabetes and cardiovascular disease [19, 33, 40, 56, 57].  Much of the 
work on adipose expansion has been done with high fat diets, while very few 
studies investigate adipose expansion with decreased activity.  Therefore, one of 
the major questions addressed in Chapter 2 is whether visceral adipose tissue 
expansion during WL occurs via hypertrophy or hyperplasia, and is this 
accompanied with an inflammatory component.
 
Figure 3.  Progression from mesenchymal precursor to mature adipocyte. 
Abbreviations: Wnt, wingless-type MMTB integration site family; Tcf, transcription 
factor; BMP, bone morphogenetic protein; MAPK, mitogen-activated protein 
kinase; cdk, cyclin-dependent kinase; p27/Kip, cyclin-dependent kinase inhibitor; 
pRb, retinoblastoma protein; CREB, cyclin AMP regulatory element-
bindingprotein; PKA, protein kinase A; PPAR, peroxisome proliferator-activated 
receptor-gamma; C/EBP, CCAAT/enhancer-binding protein; SREBP1c, sterol 
regulatory element binding protein 1c; DEX, dexamethasone; IGF1, insulin-like 
growth factor 1; cAMP, cyclic AMP; G1, S, G2, and M, G1-, S-, G2-, and M-phases 
of the cell cycle. Figure 3 was adapted from [42, 58]. 
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Catch-up fat occurs during calorie restriction-then-re-feeding and also 
during a model of physical activity-then-inactivity 
Catch-up fat is the growth of AT observed once a cause of normal growth  
is removed [59] and is often accompanied by an increase in abdominal obesity 
[40, 56, 57]. In addition, the AT phenotype that develops during catch-up growth 
is characterized by increased secretion of pro-inflammatory adipokines [59].  This 
is commonly investigated by under- then over-nutrition [59], but this also occurs 
in activity/inactivity models as both rodent models (wheel lock) and human 
models (decreased steps per day) exhibit ‘catch-up fat’ [60-62].  Another human 
correlate is the Dutch famine of 1944-1945, where exposure to famine during 
gestation and childhood was associated with impaired glucose tolerance, obesity, 
coronary heart disease, and hypertension in adulthood [63].  The catch-up fat 
concept is applicable to children’s environment, where they drastically decrease 
their daily activity after a summer vacation and sit in a classroom.  The majority 
of the literature on catch-up fat utilizes a calorie-restriction then re-feeding 
strategy.  Therefore, a major difference between our WL model and catch-up fat 
literature is mechanistic differences.  The WL model induces catch-up fat via 
increased voluntary physical activity followed by decreased caloric expenditure, 
while nutrition-based catch-up models decrease calories, then increase caloric 
intake.   
The reasons that this so-called ‘thrifty catch-up-fat phenotype’ exists and 
why catch-up growth produces harmful later health effects is not known [56, 64].  
However, the accelerated visceral AT expansion and switch to an ‘unhealthy,’ 
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pro-inflammatory phenotype documented during catch-up growth, is a likely 
contributor [65].  We have observed catch-up fat in studies performed in the 
Booth lab during periods of WL [60, 61], much like catch-up fat discussed in 
nutrition literature [59].    Both Chapter 2 and Chapter 3 address this question of 
catch-up fat during WL, but in two different contexts.  In Chapter 2, I investigate 
catch-up fat in two ages of young rats, while in Chapter 3, I investigate the effects 
of glucocorticoids on catch up fat.   
 
Physical activity maintains lower adiposity as well as a healthier adipose 
tissue phenotype 
Chronic physical activity is an important non-pharmacological means to 
reduce adiposity and disease risk.  Among a long list of benefits that physical 
activity has on physiology, protection against weight gain, decreased body fat, 
and a healthier adipose tissue phenotype are among them [66-69].  One way 
exercise does this is by maintaining lower levels of visceral adipose mass [70].  
Interestingly, exercise training can result in AT mass reduction, specifically VAT, 
independent of body mass index and/or total body weight [32, 71].  Chronic 
physical activity, like endurance training, has many other effects, one of which is 
that insulin-sensitive tissues like adipose tissue, skeletal muscle, and liver 
become more sensitive to glucocorticoids (GCs) [72].  In adipose tissue, a 
heightened sensitivity to GCs is beneficial in that there is increased lipolysis [73], 
which provides a valuable energy source for physically active animals.  However, 
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this increased sensitivity to GCs and adipose tissue lipolysis could have a 
detrimental effect for sedentary animals through increased non-esterified fatty 
acids and adipose tissue redistribution towards the viscera [74, 75].  An extreme 
example is Cushings Syndrome, which occurs due to inappropriately high levels 
of cortisol in humans.  In this context, I choose to investigate the role of GCs in 
the catch-up fat paradigm.   I wondered if the potential heightened sensitivity to 
GCs combined with a sudden decrease in physical activity contributes to the 
increased adiposity seen in our lab’s prior WL studies. 
 
Glucocorticoids and adiposity 
Glucocorticoids (cortisol in humans and corticosterone in rodents) are of 
interest because of they are known to affect adipose tissue metabolism.  While 
the role of GCs in liver and skeletal muscle is relatively clearly defined, the role of 
GCs in adipose tissue is controversial.  GCs are most commonly believed to be 
lipolytic [76], but GCs promote preadipocyte differentiation and adipogenesis 
[77]. GCs target, the glucocorticoid receptor (GR), is more highly expressed in 
visceral fat than other fat depots [78], and increased exposure to GCs in insulin-
sensitive tissues is associated with lipid accumulation and metabolic 
complications [79-83].  Interestingly, GCs affect different fat depots differently; 
they increase lipolysis in peripheral fat depots, like SAT, but they promote pre-
adipocyte differentiation and adipocyte hypertrophy in VAT [84], so there is 
something unique to VAT regarding GC action.  GC treatment in children for 
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conditions such as asthma and rheumatic diseases, inhibit weight-loss efforts 
and aggravate weight gain [85-87], and rodents with reduced GC action through 
a GC receptor block show attenuated fat increases and even induce fat loss [88].  
Because of this strong connection between GCs and adipose tissue and their 
potential to promote adiposity, I investigated the role of GCs in the inactivity-
induced catch-up fat (Chapter 3).   
 
Prior wheel lock studies and genesis of hypotheses 
   Two WL studies previously published in the Booth laboratory that 
specifically reported on adipose tissue catch-up during WL had contradictory 
results.  Both studies used the same age (rats were 28 days of age at the onset 
of voluntary wheel running) Fischer-Brown Norway F1-generation rats with ad 
libitum access to standard rat chow. In the first study, in 2005 Kump & Booth [61] 
reported that after 3 weeks of voluntary running and 2 days WL, EAT depot mass 
increased, mean adipocyte size increased, but total adipocyte number did not.  
Kump concluded that EAT expanded by hypertrophy during the 2 days of WL, 
and that the increase was due to a prolonged overshoot in triacylglycerol 
synthesis.  Then, in the second study in 2007, Laye et al. [60] reported that after 
6 weeks of running and 2 days of WL, EAT depot mass did not increase, mean 
adipocyte size did not increase, and adipocyte number did not increase.  In 
contrast to a 2-day WL, Laye et al. reported that 7 days of WL had the opposite 
effect.  EAT depot mass and total adipocyte number increased, while mean 
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adipocyte size did not increase.  In addition, Laye showed that this result is not 
due to overeating, since a pair-fed group of rats showed the same effect.  Laye 
concluded that EAT depot expanded by hyperplasia during the 7 days of WL.  
Both studies confirm that adipose tissue expands with WL.  Kump’s data showed 
hypertrophy, while Laye’s data showed hyperplasia.  There was one outstanding 
difference in experimental design; Kump performed measurements on 49-51 day 
old rats with 2 day WL, while Laye performed measurements on 70-77 day old 
rats with 7 day WL. 
These seemingly contradictory studies inspired my dissertation research.  
Given the important role adipose tissue plays in health, the dynamic nature of 
adipose tissue, and the unknown mechanism by which adipose tissue expands 
with WL, my questions were:  1) Does the way adipose tissue expands depend 
on the age of WL? (if we WL at a younger, pre-pubertal age, do we see 
hypertrophy and an older, pre-pubertal age do we see hyperplasia?)  2) How 
does adipose tissue expand with one week of WL?  (hypertrophy or 
hyperplasia?) 3) Is this expansion healthy or unhealthy?  (is there an 
inflammatory component that accompanies fat gains during WL?) 4)  Do 
glucocorticoids play a role in this adipose tissue expansion?  (if we block GC 
action, could we attenuate the fat mass gains?).  I used two different ages of rats 
(49-56 days of age and 70-77 days of age) to represent the two previous studies 
performed in our lab as well as represent two ages of pre-pubertal growth.  49-56 
days of age is prior to-sexual maturity, while 70-77 days of age is near or at-
sexual maturity [89]. 
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Overall Hypothesis and specific aims for the two studies presented 
My overall hypothesis was that seven days of wheel lock in rats that are 
49-56 days old and rats that are 70-77 days old would result in gains in visceral 
adipose mass seen in age-matched sedentary rats concurrent with an increase in 
adipocyte size and inflammatory mRNA expression.  Further, glucocorticoid block 
would attenuate the visceral adipose depot gains seen in WL in 70-77 day old 
rats.     
Specific hypothesis in Chapter 2: I tested the hypothesis that 7 days of wheel 
lock would: a) increase the rate of percent body fat growth and adipose depot 
masses to levels seen in age-matched SED rats in both ages of rats; b) result in 
a visceral adipose depot expansion via hypertrophy in rats 49-56 days of age and 
via hyperplasia in rats 70-77 days of age, and c) increase inflammatory mRNAs 
in adipose tissue before other selected categories of mRNAs in rats 49-56 days 
of age but not 70-77 days of age.  The aim of this study was to 1) address how 
adipose tissue expands with WL and determine whether an increase in 
inflammatory mRNA expression is present and 2) determine whether timing of 
WL (49-56 days of age or 70-77 days of age) affects outcomes of adipocyte size 
and number, and of whether inflammatory mRNAs profile would differ between 
these two groups. 
Specific hypothesis in Chapter 3: I tested the hypothesis that when compared to 
WL rats, rats that had “access to voluntary running wheels” and rats that 
“underwent WL plus a glucocorticoid receptor block” would show similar changes 
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as “WL rats” in PRAT transcript expression involved in cell cycle, proliferation, 
and differentiation.  This hypothesis was generated from the finding in Chapter 2 
where we found that cyclin A1, a marker of proliferation and total adipocyte 
number was increased in PRAT and EAT depots in W L rats.  
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CHAPTER 2 
 
 
 
STUDY 1: 
 
SUDDEN DECREASE IN PHYSICAL ACTIVITY EVOKES ADIPOCYTE 
HYPERPLASIA IN 70-77 DAY OLD RATS, BUT NOT 49-56 DAY OLD RATS 
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ABSTRACT 
 
The cessation of physical activity in rodents and humans initiates 
obesogenic mechanisms.  The overall purpose of the current study was to 
determine how the cessation of daily physical activity in rats at 49-56 days of age 
and at 70-77 days of age via wheel lock affects adipose tissue characteristics.  
Male Wistar rats began voluntary running at 28 days old and were either 
sacrificed at 49-56 days old or at 70-77 days old.  Two cohorts of rats always had 
wheel access (RUN), a second two cohorts of rats had wheel access restricted 
during the last seven days (7d-WL), and a third two cohorts of rats did not have 
access to a voluntary running wheel after the first 6 days of running (SED).  We 
observed more robust changes with WL in the 70-77 day old rats.   Compared to 
RUN rats, 7d-WL rats exhibited greater rates of gain in fat mass and % body fat, 
increased adipocyte number, higher percentage of small adipocytes, and greater 
cyclin A1 mRNA in epididymal and perirenal adipose tissue.  In contrast, 49-56 
day old rats had no change in most of the same characteristics.  There was no 
increase in inflammatory mRNA expression in either cohort with WL.  There was 
a disconnect between decreased food intake and increased adiposity, suggesting 
that reduced caloric intake does not reduce body fat when physical activity is 
reduced simultaneously.  These findings suggest that adipose tissue in 70-77 
day old rats is more greatly affected by WL than 49-56 day old rats and responds 
by expansion via hyperplasia.   
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INTRODUCTION 
Increased childhood physical inactivity is associated with the rise in 
childhood obesity.  Specifically, an increased prevalence of physical inactivity 
occurs as children age to adolescents in the U.S. [1, 3].  While over 70% of girls 
and over 95% of boys 6- to 8-yrs old meet the recommend daily activity 
guidelines of 60 minutes of moderate- to vigorous activity daily, less than 15% of 
girls and less than 43% of boys 12- to 14-yrs old meet the same requirements.  
In addition, the U.S. prevalence of obesity was 12.1% among children aged 2 
through 5 years, 18.0% among children aged 6-11 years old, and 18.4% among 
adolescents aged 12 through 19 years old [4]. Thus, obesity prevalence 
increases ~50% when advancing from the 2-5 year old age group to the 6-11 
year old age group, but does not further increase in the 12-19 year old age 
group.  Taken together, these statistics highlight a growing crisis in public health 
as children become less active, which coincides with fat gain during decisive 
periods of growth and development that include various ages of pre-pubertal 
growth.   
Adipose tissue is now well-recognized as an endocrine organ capable of 
demonstrating an inflammatory/immune component [90, 91].  Further, the 
function of adipose tissue depends on its localization [23] with visceral fat more 
closely associated with an increased risk of developing a metabolic syndrome 
[92, 93].  Adipose tissue is highly plastic and responds rapidly to environmental 
changes and can expand by either hypertrophy (increase in the size of an 
adipocyte) or hyperplasia (increase in the number of adipocytes).  It is believed 
that adipose tissue expansion by hypertrophy, especially visceral adipose tissue 
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(VAT) expansion, leads to an unhealthy, pro-inflammatory phenotype that is 
concurrent with the development of metabolic complications and is a risk factor 
for type 2 diabetes and cardiovascular disease [19, 33, 40, 56, 57].  Conversely, 
adipose tissue expansion via hyperplasia retains a healthy, anti-inflammatory 
phenotype that is associated with positive metabolic consequences including 
maintained insulin sensitivity, and favorable blood lipids [53] even in the 
presence of obesity [54].  Dulloo [40] has described large decreases in body 
weight followed by weight recovery occur during infancy, childhood, or adulthood.  
In most cases, body fat, specifically visceral fat, is recovered via hypertrophy at a 
disproportionately faster rate than lean tissue (termed “catch-up fat”).  These 
concepts regarding fat gain are important to the childhood obesity conversation 
because puberty is a critical time of adipose tissue expansion [5] where the 
number of adulthood adipocytes is generally set [6]. Taken together, it is clear 
that environmental events early in life influence adipocyte number, adipose tissue 
distribution, and adipose tissue plasticity later in life [94]. Still, insufficient 
information is known about the acute mechanisms behind adipose tissue 
expansion at various ages of pre-pubertal growth.  
Animal models that allow study of adipose tissue plasticity within the 
abdominal cavity in an inactivity context are invaluable in gaining an 
understanding into potential negative consequences of early childhood inactivity 
and fat gain. Our laboratory has successfully employed a “rodent wheel lock 
model” (abbreviated “WL”) where we allow pre-pubertal rats access to a 
voluntary running wheel for a period of time (4-6 wks) and then “lock” the wheel 
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for one week to study the effects of transitioning from high levels of physical 
activity to low levels of physical activity on adipose tissue expansion [8, 60, 61, 
95].  In essence, the environmental factor of physical activity is “knocked down”, 
analogous to knock out of a gene to study gene-environment interaction.  The 
notion is somewhat similar to the concept of “catch-up” fat [59], whereby re-
feeding occurs after caloric restriction.  Distinctively though, the genesis of 
enhanced adipose tissue growth differs between the WL and “catch-up” fat 
models.  We speculate that subtle mechanistic differences between the two 
processes.  The WL model increases voluntary physical activity then decreases 
physical activity, implying decreased caloric expenditure, which suggests that a 
physical activity-induced metabolic change influences adipose metabolism.  The 
“classical” catch-up fat model that decreases calories, then increases positive 
caloric intake suggests a net caloric balance influence on adipose metabolism.  
Importantly, both models induce the trajectory in adipose tissue mass to turn 
upward. 
Previous work in our laboratory showed that WL resulted in the following 
adipose tissue changes:  1) in 49-day old male rats, 2 days of WL induced an 
increase in epididymal fat mass via hypertrophy [61]; while 2) in 70-day old male 
rats, one week of WL resulted in the epididymal adipose tissue depot expansion 
via hyperplasia [60].  As these differences remain unresolved, we hypothesized 
that this incongruity could be related to the onset of WL occurring at 49 days of 
age versus 70 days of age. Therefore, to further understand the dynamic 
adaptation of fat during WL, the overall purpose of this experiment was to 
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determine what role pre-pubertal age (49-56 days of age versus 70-77 days of 
age)  plays in affecting catch-up growth of adipose tissue mass and adipocyte 
size in three visceral depots when physically active male rats undergo one week 
of WL (7d-WL). Two specific purposes were to determine whether WL in 49-56 
day of rats and/or 70-77 days of age differentially altered the following: 1) 
adipose tissue characteristics (mass and/or adipocyte size and adipocyte 
number); and 2) the mRNA expression of pro-inflammatory, hypoxic, adipokine, 
and adipogenic genes.  Of note, age-matched sedentary controls (SED) and rats 
that had continual running wheel access (RUN) were also assayed in order to 
stratify WL animals between these two control groups.  We hypothesized that 7 
days of WL would: 1) increase the rate of percent body fat growth and adipose 
depot masses to levels seen in age-matched SED rats in both ages of rats; 2) 
result in a visceral adipose depot expansion via hypertrophy in rats 49-56 days of 
age and via hyperplasia in rats 70-77 days of age; and 3) increase inflammatory 
mRNAs in adipose tissue before other selected categories of mRNAs in rats 49-
56 days of age but not 70-77 days of age. 
 
METHODS 
Animals and Experimental design 
The University of Missouri animal Care and Use Committee approved 
experimental protocols.  Two similar protocols were employed at two distinct age 
groups:  Protocol 1, “49-56 day old rats” and Protocol 2, “70-77 day old rats” The 
rationale for this is that we have previously employed the WL model on two ages 
of rats with differing results on hyperplasia and hypertrophy of adipocytes [60, 
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61]. Therefore, we performed WL on two ages, 49-56 days old and aged 70-77 
days old to: 1) match previous ages performed in our laboratory [60, 61, 95] and 
2) determine if there was an age-related difference in characteristics of adipocyte 
enlargement in response to WL. 
Protocol 1.  34 male, Wistar rats were randomly selected from a 
population of Wistar rats bred in our laboratory (Fig. 2.1A). The rats were weaned 
at 21 days of age and housed as pups in a single cage.  At 28 days of age, rats 
were placed into individually housed cages with a voluntary running wheel 
equipped with a Sigma Sport BC 800 bicycle computer (Cherry Creek Cyclery, 
Foster Falls, VA) in order to select the highest distance runners in an experiment 
whose primary outcome was selective breeding of high voluntary distances [96].  
After 6 days, 12 rats were randomly selected to be sedentary for the remainder of 
the experiment for 21 or 28 days (49d SED and 56d SED), were removed from 
the cages with voluntary running wheels, and were individually housed in 
standard rat cages without voluntary running wheels respectively (note that the 
first number in the group name refers to age of rats).  The remaining 22 rats were 
randomly assigned to running groups (49d RUN, 56d RUN and 56d 7d-WL) and 
remained in cages with voluntary running wheels (note that 7d-WL in the group 
name refers to 7 days of wheels being locked for the final 7 days of the treatment 
period).  At the end of week 3, 8 rats were randomly selected to undergo WL, 
whereby a stainless steel rod was placed through the running wheel, thus 
prohibiting the running wheel from turning (56d 7d-WL).  All rats were housed in 
the same temperature-controlled animal room (21oC) and maintained on a 12-h 
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light (07.00 h- 19.00 h), 12-h (19.00 h-07.00 h) dark cycle.  All rats had ad libitum 
access to standard rodent chow (Formulab 5008, Purina Mills, St Louis, MO, 
USA) and water.  Running activity, as determined by distance and time ran 
during the previous 24 h, was recorded daily.  Animal cages were changed every 
7 days at which time body weight and weekly food intake was recorded.  This 
protocol had been used previously in our lab [61]. 
Protocol 2.  40 male, Wistar rats were randomly selected from a 
population of Wistar rats bred in our laboratory (Fig. 2.1B).  The design is the 
same as Protocol 1 except for duration of wheel running being 3 wks longer, the 
day of WL (day 70), and day of sacrifice (day 77) (see Fig. 2.1B for details).  In 
short, rats in Protocol 2 began treatment at the same age as rats in Protocol 1, 
but were 3 wks older at the time of WL and sacrifice and thus were exposed to 
voluntary running wheels (70d RUN, 77d RUN, and 77d 7d-WL) or no voluntary 
running wheels (70d SED and 77d SED) 3 wks longer than the rats in Protocol 1.  
During the final week, food intake for 77d 7d-WL was measured daily.  This 
protocol had been used previously in our lab [60, 61].   
Animal sacrifice 
 Immediately after CO2 asphyxiation between 1000-1200 hrs, rats were 
weighed and DXA scanned as mentioned previously.  Four fat pads were 
collected in Protocol 1 and 2: omental adipose tissue (OMAT), epididymal 
adipose tissue (EAT), perirenal adipose tissue (PRAT), and subcutaneous 
adipose tissue (SAT).  The entire OMAT, EAT, and PRAT depots were removed  
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and weighed, while a portion of umbilical/groin SAT was collected.  A section of 
each fat depot was snap-frozen in liquid nitrogen and stored at -80C for real-
time reverse transcriptase polymerase chain reaction (RT-PCR) mRNA analysis 
and another section was saved for adipocyte sizing. 
 
RT- PCR for adipose tissue mRNA expression patterns 
Approximately 100 mg frozen AT was homogenized in 1 ml RNA lysis 
buffer (Tri Reagent – Sigma) using a high-speed shaking device with a stainless 
steel bead at 30 Hz for 1 min (Tissuelyser LT, Qiagen, Valencia CA). RNA was 
isolated using the method according to manufacturer’s instructions (Tri Reagent 
– Sigma, St. Louis, MO) and lack of RNA degradation was verified on a 1% 
agarose gel.  1 µg of RNA was DNase-treated using DNase I (Thermo Scientific, 
Glen Burnie, MD) and reverse transcribed using a High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems, Carlsbad, CA).  Gene-specific primers 
were constructed (Table 2.1) and primer efficiency curves were produced for all 
genes. Primer efficiencies ranged between 90-110% for all genes. Twenty-five ng 
of cDNA was assayed (NanoDrop 1000  –ThermoScientific) from each sample in 
duplicate for the targets listed in Table 2.1 using SYBR green chemistry (Power 
SYBR green Mastermix – Applied Biosystems).  mRNA expression values are 
presented as 2ΔΔCT whereby ΔCT = B2M CT – gene of interest CT and were 
normalized to 49d RUN.  
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TNF-α: Tumor Necrosis Factor-alpha; IL-6: Interleukin-6; MCP-1: Monocyte Chemoattractant Protein-1; HIF-
1α: Hypoxia-Inducible Factor-1 alpha subunit; VEGF: Vascular Endothelial Growth Factor; CDK2: Cyclin-
Dependent Kinase 2; PPARγ: Peroxisome Proliferator-Activated Receptor gamma; C/EBPα: 
CCAAT/enhancer binding protein alpha. 
 
Adipocyte sizing and number 
Adipocyte sizing was performed on EAT in Protocol 1 and three visceral 
AT depots: OMAT, EAT, and PRAT in Protocol 2 using techniques described 
previously [60].  Briefly, three 60-80 mg adipose tissue fragments per depot per 
animal were placed in a glass scintillation tube containing 3 ml Krebs-Ringer-
HEPES buffer (KRBH; 130 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 10 mM 
HEPES, 1 mM CaCL2, 1.2 mM MgSO4, 0.25 mg/ml free fatty acid-free BSA, pH = 
7.4).  Fragments were subsequently minced into ~1mm3 pieces, incubated with 
0.920 Wunsch units of Liberase Blendzyme (Roche) in a 37oC incubator at 100 
rpm for 1 hour, and then transferred through a sterile 200 µm nylon mesh (Sefar 
America, Kansas City, MO) into a 15 ml conical tube.  After centrifugation at 100 
rpm for 1 minute, the adipocytes were loosely packed at the top of the liquid and 
the bottom layer of liquid was removed using a syringe and needle.  The 
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adipocytes were washed with ~5 ml KRBH then resuspended in 5 ml KRBH for 
every 1 ml of loosely packed adipocytes.  A random sample of the adipocytes 
was viewed with a Nikon Eclipse E600 microscope and photographed by an 
Olympus DP72 camera.  The diameter of >300 adipocytes were measured using 
DP2-BSW v2.1 software.  The mean diameter and size distribution were 
calculated for each adipocyte depot.   
The number of adipocytes per depot was calculated with the mass of the 
fat depot, a density conversion factor (0.915 ng lipid/1 pl), and average diameter 
of adipocytes [97].  Briefly, the average cell mass was calculated by: average cell 
size (pl) x 0.915 (ng lipid/1 pl) x g/109 ng.  The number of cells per depot was 
calculated as: mass of adipose depot (g) / average mass of adipocyte (g).  
Reliability of this method is described in detail [97] and has been used by others 
[98]. There are two ways to present adipocyte cellularity: number of cells per 
depot and number of cells per gram of adipose tissue.  The rationale for 
presenting adipocyte cellularity as “number of cells per depot” is that an 
underlying question was whether visceral adipose tissue was expanding by 
hypertrophy or hyperplasia.  To address this, it was necessary to calculate an 
estimate of total adipocytes in a depot.  The problem with expressing adipocyte 
cellularity as “adipocytes per gram of adipose tissue” is that, while it addresses 
cell density, it does not prove hyperplasia.  For example, if we see an increase in 
cell density (more adipocytes per gram of tissue), we can conclude that either, 1) 
hyperplasia is occurring and new adipocytes are being formed and causing the 
increased density or 2) lipolysis is occurring and current adipocytes are shrinking 
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and causing the increased density.  Because of this uncertainty, adipocyte 
cellularity is expressed as “number of adipocytes per depot.” 
 
Statistical analysis 
Outcome measures for between-group or within-group comparisons 
(adipose depot mass, adipocyte size, adipocyte size distribution, and RT-PCR) 
were analyzed with a one-way analysis of variance.  For outcome measures that 
had the same measures on the same animal (weekly body weight, daily distance 
run, and weekly food intake), a two-way analysis of variance was performed 
(group x time).  Significant main effects (p < 0.05) were followed up with Fisher 
LSD post hoc comparisons.  Sigmaplot 12.0 (San Jose, CA) was used for all 
statistical analyses. Values are reported as means ± SE, and significance for all 
tests was set at p < 0.05. Exceptions to these statistical methods are stated in 
figure legends.   
 
RESULTS 
Daily running distances.  RUN only (77d RUN), and RUN followed by 7d-
WL groups (hereafter referred to as 7d-WL) ran similar distances during the 
treatment period (Fig. 2.2).  All 70-77 day old groups (70d RUN, 77d 7d-WL, and 
77d RUN) appeared to reach a plateau in nightly running distance by the 4th 
week of running.  
 
 
29 
 
 
30 
 
 Weekly body weights.  Gains in body weight expressed as grams gained 
per week for all groups are consistent through 49 days of age in both age groups 
of rats then decrease through 77 days of age (Fig. 2.3C and 2.3D).  Importantly, 
in 49-56 day old rats, WL was performed before any notable drop in grams 
gained per week.  In contrast, in 70-77 day old rats, WL was performed at an age 
where grams gained per week had significantly decreased.   Body mass growth 
during WL (56d 7d-WL) between the ages of 49-56 days paralleled growth in the 
56d RUN and 56d SED groups (Fig. 2.3A and 2.4A).  However in three-week 
older rats, body mass growth during WL (77d 7d-WL) no longer paralleled 77d 
RUN and 77d SED (Fig. 2.3B and 2.4E). 
 
Body mass, DXA lean body mass, DXA fat mass, and DXA percent body 
fat during wheel lock.  WL rats showed an increased rate of fat mass gain and 
body fat % gain compared to RUN rats in both 49-56 day old rats (Fig. 2.4C & 
2.4D, different capital letters represent different slopes) and 70-77 day old rats 
(Fig. 2.4G & 2.4H, different capital letters represent different slopes), so that the 
slope of gain during WL was similar to SED.  It is notable that the slope of % 
body fat was significantly less between both 49-56 days and 70-77 days in 56d 
RUN and 77d RUN versus the respective upward slopes of WL (Fig. 2.4C and 
2.4F), and gains in % body fat were attenuated in 56d RUN rats compared to 56d 
7d-WL and 56d SED. WL did not affect lean body mass gains in either age group 
(Fig. 2.4B & 2.4F).  
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Weekly food intake in 70-77 day old rats. Apart from week 7, there was no 
activity effect on weekly food intake (Fig. 2.5A).  All groups reached a relative 
steady-state in food intake by week 4 and, with the exception of 77d 7d-WL, 
remained constant through week 7.  Three days after WL, 77d 7d-WL rats 
decreased food intake and maintained this level for the remaining four days (Fig. 
2.5B), indicating a rapid response in appetite to decreased activity as food 
intakes were tending to show progressive drops already on 1st and 2nd days of 
WL.  
Feed efficiency in 70-77 day old rats.  77d SED rats had greater weekly 
feed efficiency during weeks 3, 5, and 7 compared to RUN rats, but WL 
increased weekly feed efficiency to SED levels (Fig. 2.6A), despite a rapid 
decrease in food intake (Fig. 2.5B).  Day-to-day feed efficiency during WL 
showed a transient one-day increase in feed efficiency at day 1 of WL followed 
by an abrupt decrease and plateau in feed efficiency to pre-WL levels from days 
2-7 days of WL (Fig. 2.6B), which highlights the impact a sudden decrease in 
activity has on energy homeostasis.   
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Adipose tissue depot mass.  49-56 day old rats’ adipose tissue mass 
increased independent of activity level (49d RUN < 56d RUN and 49d SED < 56d 
SED) (Fig. 2.7A-C), suggesting that these rats are ‘growing’ in terms of body 
mass and adipose depot mass whether they are physically active or not.  WL did 
not affect this increase (56d RUN = 56d WL) in all three depots (Fig. 2.7A-C).  In 
contrast, 70-77 day old rats’ adipose tissue mass has reached a plateau and did 
not increase between 70-77 days (70 RUN = 77 RUN and 70 SED = 77 SED) 
(Fig 2.7D-F), suggesting that these rats are not ‘growing’ in terms of adipose 
depot mass as rapidly as 49-56 day old rats.  WL induced mass gains between 
70-77 days (77 RUN < 77 WL) in EAT and PRAT (Fig 2.7D and 2.7E). 
Adipocyte diameter.  Adipocyte diameter data trends follow depot mass 
trends.  49-56 day old rats’ EAT adipocytes appear to expanding via hypertrophy 
independent of activity level (49d RUN < 56d RUN and 49d SED < 56d SED) 
(Fig. 2.8 A), and WL did not affect this (56d RUN = 56d 7d-WL) (Fig 2.8 A).  70-
77 day old rats’ adipocyte diameter reached a plateau (70d RUN = 77d RUN and 
70d SED = 77d SED) (Fig 2.8B-D).  WL increased adipocyte diameter (77d RUN 
< 77d 7d-WL) in EAT and PRAT (Fig 2.8E and 2.8F).   
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Total adipocyte number in depot.  WL did not affect total adipocyte 
number in EAT in these 49-56 day old rats (56d RUN = 56d 7d-WL), emphasizing 
that the increased total number of adipocytes between 49d RUN and 56d 7d-WL 
was not due to WL, it was due to aging.  In 70-77 day old rats, total adipocyte 
number reached a plateau in all three depots (70 RUN = 77 RUN and 70 SED = 
77 SED) (Fig 2.8 B-D).  WL increased total adipocyte number in EAT and PRAT 
(77 RUN < 77 WL) in EAT and PRAT (Fig 2.8B and 2.8C).  
Taken together, the adipocyte depot mass, adipocyte diameter, and total 
adipocyte number in a depot data suggests that 1) adipose tissue in 49-56 day 
old rats is still expanding with 7 days of age while it is not in 70-77 day old rats. 
2) WL does not alter this adipose tissue expansion in 49-56 day old rats, while it 
increases depot mass and total adipocyte number in 70-77 day old rats.   
 
Adipocyte size distribution.  Activity and age affect adipocyte size 
distribution, and WL alters the adipocyte size distribution in EAT and PRAT 
depots.  In 49-56 day old rats EAT, there is a rightward shift in the 56d 7d-WL 
group that parallels the shift seen in the 56 RUN group, but there are two distinct 
differences:  1) there is a ‘flattening out’ of the 56d 7d-WL curve such that the 
peak is lower than 56 RUN, and 2) 56d 7d-WL has more adipocytes in the 40 µm 
category than 56d RUN (Fig. 2.9A), a finding that may indicate the formation of 
smaller adipocytes via hyperplasia is occurring. In contrast, the rightward shift in 
EAT is absent in 70-77 day old rats within the 77d 7d-WL group, but there are 
more ‘small’ adipocytes at 20-, 30-, and 40- µm categories (Fig. 2.9B); again, this 
40 
 
being a finding that may indicate the formation of smaller adipocytes via 
hyperplasia is occurring.  Similar to 70-77 day old rats’ EAT, PRAT also shows a 
‘flattening out’ of the 77d 7d-WL curve with more ‘smaller’ adipocytes at 30- and 
40-µm categories (Fig. 2.9C).  77d 7d-WL OMAT shows a rightward shift, but 
little to no flattening out (Fig. 2.9D).  
Apart from the WL effect described above, there was a physical activity 
effect and age effect on adipocyte distribution. In both the 49-56 day old rats and 
70-77 day old rats, SED rats showed an apparent rightward shift in the peak 
percentage adipocyte diameter such that for all age-matched groups RUN < SED 
(Fig. 2.9).  Objectively, the mean diameter was greater in SED compared to 
RUN.  Subjectively, the curve is visually shifted to the right in SED compared to 
RUN.  In the 49-56 day old rats, a rightward shift in the peak percentage from 49 
days of age to 56 days of age was observed in both RUN and SED so that 49 
RUN < 56 RUN and 49 SED < 56 SED (Fig. 2.9A), implying that at this age, 
adipocytes are still in a growth phase, and this growth occurs independent of 
activity level.  In contrast, this rightward shift is not present in the 70-77 day old 
rats: 70d RUN = 77d RUN and 70d SED = 77d SED (Fig. 2.9B-D) implying that 
the adipocyte growth has reached a steady-state at sexual maturity. 
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Figure 2.9. Adipocyte size distribution  
Adipocyte diameters were classified in 10-µm categories (10: 0.0-9.9 µm, 20: 10.0-19.9 µm, 30: 20.0-29.9 
µm, etc.) and the percentage of total adipocytes in a sample was plotted for each category. At least 300 
adipocyte diameters were measured for each tissue sample. Same letters are statistically the same among 
groups at each category, p<0.05. 
 
WL increased cyclin A1 mRNA expression to SED levels in 70-77 day old 
rats EAT, PRAT, and SAT, but not in OMAT.  There was a physical activity effect 
on cyclin A1 mRNA levels in 70-77 day old rats such that RUN expressed less 
cyclin A1 mRNA than SED or 77d 7d-WL in EAT, PRAT, and SAT, but not OAT 
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(Table 2.2, Fig. 2.10B).  This data suggests that voluntary wheel running may act 
as a ‘brake’ that attenuates expression of this proliferation gene in some, but not 
all fat depots, and removing this ‘brake’ via extraneous inactivity increases a 
marker of adipocyte hyperplasia, cyclin A1 [99].  There were no differences in 
cyclin A1 mRNA in 49-56 day old rats, suggesting that adipose tissue depots are 
still in the process of expanding and new adipocytes are still being formed 
regardless of physical activity level.  In addition to cyclin A1 mRNA increases, 
WL increased HIF-1α mRNA to 77d SED levels in EAT and paradoxically 
decreased IL-6 mRNA of 70d RUN rats in PRAT.   
 
 Figure 2.10. mRNA expression of cyclin A1  
Panel A:  49-56 day old rats cyclin A1 mRNA expression was normalized to 1.0 for 49d RUN SQ (red bar). 
There were no differences between groups within each depot.  Panel B:  70-77 day old rats cyclin A1 mRNA 
expression was normalized to 1.0 for 70d RUN SQ (red bar).  Different letters indicate significant differences 
among groups in each depot, p<0.05.  OMAT = omental adipose tissue; EAT = epididymal adipose tissue; 
PRAT = perirenal adipose tissue; and SQAT = subcutaneous adipose tissue.  Same letters are statistically 
the same.  
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DISCUSSION 
In the current study, we examined two life phases in rats whose ages were 
selected to mimic a phase of human life where: 1) adipocyte number rapidly 
increases and then stabilizes [5, 6, 10, 94] and 2) prevalence of U.S. childhood 
obesity and physical inactivity both simultaneously increase 50% from the age 
ranges of 6-8 yrs to 12-19 yrs of age [see introduction for details and refs [1, 8, 
100]].  We report: 1) compared to 49-56 day old rats, adipose tissue in 70-77 day 
old rats is more greatly affected by WL and responds by expansion via 
hyperplasia; 2) in both ages, WL occurs without an increase in inflammatory 
mRNA expression; 3) only in 70-77 day old rats did 7d-WL increase cyclin A1 
mRNA above RUN levels, reaching the higher sedentary levels in EAT, PRAT 
and SAT (Fig. 2.10).  We thus propose for the first time to our knowledge the 
notion that the type of adipocyte growth mechanism (i.e., hypertrophy or 
hyperplasia) is dependent on stage of growth during WL.  
 
Rate of growth decreases between 49-56 days of age. 
The two ages of rats exhibited different growth accretions, forming a 
novel, two-phase process dependent on pre-pubertal age (Fig. 2.11).  49-56 day 
old rats appeared to show no effect of WL in many of our outcome measures 
(Table 2.3). We observed a decrease in the increment of weekly gains in 
absolute body mass gains beginning around 49-56-day age interval (Fig. 2.3). 
This data suggests that 49-56 day old rats are in a more rapid growth phase and 
are near to an inflection point indicating a new phase of slower growth is 
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beginning.  This is important because the progressively slower gain in body mass 
starting at 49 days old may be associated with the previously reported shutting 
down of adipocyte proliferation with maturation in sedentary rats [10].  
Importantly, the 49-56 day old rats’ data was collected at 49 and 56 days of age, 
essentially at the end of the rapid growth phase, while in the 70-77 day old rats’ 
data was collected at 70 and 77 days of age, three weeks into the progressively 
slower growth increments.  Together, these observations set a unique two-phase 
construct upon which we examined for any co-clustering of directional changes 
or of no change.   
 
Comparisons of 9 outcome measures (body mass, lean mass, % body fat, adipose tissue depot mass, 
adipocyte diameter, total number of adipocytes in a depot, adipocyte size distribution, and Cyclin A1 mRNA 
expression) between 56d RUN and 56d 7d-WL rats in the 49-56 day old group and between 77d RUN and 
77d 7d-WL in the 70-77 day old group.  EAT: epididymal adipose tissue, PRAT: perirenal adipose tissue, 
OAT: omental adipose tissue, SAT: subcutaneous adipose tissue.   
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Figure 2.11. Summary Figure  
Proposed two-phase construct illustrating differences observed between 49-56 day old rats and 70-77 day 
old rats in outcome measures examined for any co-clustering of directional changes or of no change. The x-
axis represents the final 7 days of the experiment, either 49- to 56-days of age or 70- to 77-days of age..  
The y-axis represents the observed change in a given outcome measure over the final 7 days of the 
experiment.  The black line represents both 56d RUN and 77d RUN groups and represents the entire 
change observed (100%) over the last week. The two, gray dashed lines represent 56d 7d-WL and 77d 7d-
WL groups.  These lines represent changes observed in outcome measures relative to their respective RUN 
groups.  In general, we observed almost no changes with WL in the 49-56 day old rats, while we noted many 
outcomes increase in the 70-77 day old rats.   
 
Age of WL affects adipose tissue response 
EAT in 49-56 day old RUN rats showed increased adipocyte size between 
49 and 56 days of age even though they continued running, suggesting that 
these rats are in a hypertrophic growth phase.  However the effect of WL 
appears to be ‘lost’ or ‘masked’ due to the natural expansion occurring with 7 
days of age.  In contrast, is seems clear that WL in 70-77 day old rats induces a 
hyperplasic response.  There was a clear plateau in total adipocyte number in a 
depot between 70 and 77 days of age in both RUN and SED rats in all depots.  
WL induced an increase in total adipocyte number in EAT and PRAT.  Age-
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matched run rats (77d RUN) did not exhibit this increase in total adipocyte 
number, thus the hyperplasic expansion in 70-77 day old rats is due to WL, not 
age.  These findings are novel and suggest that the age in which a decrease in 
activity occurs influences the expansion characteristics of visceral adipose tissue. 
WL alters adipocyte size distribution  
In the 49-56 day old rats, there is a clear rightward-shift with age.  The 56d 
RUN and 56d SED curves are to the right of the 49d RUN and 49d SED curves, 
suggesting hypertrophic adipose tissue expansion.  The WL curve shows a 
rightward-shift compared to 49d RUN, but also shows a flattening and increased 
number of adipocytes in the 40 m category.   In contrast, in the 70-77 day old 
rats, there is no longer a rightward-shift observed between the RUN groups or 
the SED groups in EAT and PRAT depots, suggesting that hypertrophic adipose 
expansion is no longer occurring.  However, WL flattened the curve in both EAT 
and PRAT and showed more adipocytes in the 30- and 40 m categories.  The 
emergence of small adipocytes has been observed by others: weight-regain after 
calorie restricted weight loss in older rats [98, 101] and thiazolidinedione 
treatment in rodents [102], but this is the first time this has been measured in 
inactivity-induced fat mass increase in young rats.  This data supports the 
supposition that 49-56 day old rats are still expanding adipose tissue by 
hypertrophy, while 70-77 day old rats are no longer expanding adipose tissue.  In 
contrast to the other depots, the OMAT WL curve exhibited a rightward shift with 
no increase in smaller adipocytes, suggesting that OMAT adipocytes respond to 
WL by hypertrophy.  Tchkonia et al. [103] reported that human omental pre-
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adipocytes have lower potential for replication and differentiation than 
subcutaneous or mesenteric pre-adipocytes in morbidly obese adult humans.  
While our rats were younger and not obese, this lower proliferation and 
differentiation potential in OMAT may explain the different response to WL in 
OMAT compared to EAT and PRAT. 
 
There was no increase in inflammatory mRNA expression with WL 
We measured three inflammatory markers, plus two hypoxic markers and 
found no increases in any of these with WL.  Hypoxia markers were selected 
because hypoxia is implicated in early adipose tissue expansion and is a 
precursor to inflammation [104-106]. The lack of an inflammatory response may 
be due to hyperplasic adipose expansion, which is associated with a healthy 
adipose tissue adaptation [43].   Another explanation is that the adipose tissue 
expansion was not sufficient to evoke an inflammatory response.  Many of the 
studies where an inflammatory response was observed used either longer 
periods of observation and/or a more severe induction of adiposity, like a high fat 
diet, [19, 107, 108] or gene alteration [109, 110].  While we can say that 
increases in adipose tissue mass seen with a sudden decrease in activity are not 
accompanied by a pro-inflammatory phenotype in these young rats, we are not 
certain of the effects of decreased activity as these animals age.   
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WL cyclin A1 mRNA expression equaled that of SED and was greater than RUN 
We found new evidence that suggests cell proliferation is increased EAT, 
PRAT and SAT in WL rats.  Cyclin A1 is a marker of proliferation, as its protein 
functions to promote cell proliferation and survival by its requirement for S phase 
and passage through G2 [111, 112].  Cyclin A1 mRNA was greater in 77d 7d-WL 
than in 77d RUN group for 3 adipose tissue depots (EAT, PRAT, and SQAT), 
without similar differences between 56d RUN  and 56d 7d-WL (Fig. 2.10).  The 
emergence of a higher proportion of small adipocytes (<30 µm) in EAT and 
PRAT of 70-77 day old rats after one week of WL combined with the increase in 
cyclin A1 mRNA expression supports the notion of an inactivity-induced 
proliferation of preadipocytes and/or differentiation of preadipocytes present in 
7d-WL depots.  We previously reported the occurrence of hyperplasia in the EPI 
depot with 7d-WL [60], and others have found adipocyte proliferation to occur 
with weight regain after calorie restriction in rats, [98, 101, 113] and in weight-
reduced humans [114].  Thus, we suggest the novel idea that physical activity 
acts as a ‘brake’ on adipose tissue expansion via hyperplasia in 70-77 day old 
rats, and once that ‘brake’ is removed (i.e., WL), adipose tissue expands 
primarily by hyperplasia. The preferential increase in cyclin A1 prior to other 
mRNA changes in only the 70-77 day old WL group supports formation of the 
following hypothesis:  an upstream ‘activity’-dependent signal to the cell cycle, 
and not a pro-inflammatory adipokine, is an early signal to increase hyperplasia. 
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Adipose tissue depots responded differently to WL 
The above data clearly shows that the three adipose depots respond 
differently to WL in 70-77 day old rats. We speculate that differential responses 
among intra-abdominal fat depots are most likely to be due to intrinsic differences 
in gene programming in various intra-abdominal fat depots and to age, rather 
than to the stage of sexual maturity, as the latter is a commonality to the various 
intra-abdominal fat depots.  In support of our notion, it has previously been 
reported that the inherent proliferative capacity of adipose depots vary: SAT > 
PRAT > EAT > mesenteric AT [115], as well as metabolic differences between 
depots [35].  
A differential response in adipose tissue depots may have clinical 
implications given that new, smaller adipocytes have greater capacity to 
preferentially accumulate fat compared to larger adipocytes, and thereby buffer 
the onset of the metabolic syndrome.  In addition, smaller adipocytes are less 
sensitive to anti-lipolytic effects of insulin [116], they exhibit lower rates of basal 
and catecholamine-stimulated lipolysis [117, 118], and they are more protective 
against metabolic disease as compared to very large adipocytes [54]. The 
emergence of small adipocytes has been observed by others: weight-regain after 
calorie restricted weight loss in older rats [98, 101] and thiazolidinedione 
treatment in rodents [102].  Therefore, we speculate that the failure of omental 
adipocytes to proliferate during WL in 70-77 day old rats could play a contributing 
role to omental adipose tissue being an unhealthier adipose tissue depot. 
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Resolution of previous data discrepancies. 
We previously reported that during WL, adipocyte hypertrophy 
predominated during increased EAT mass in Fischer 344 Brown Norway rats 
aged 42-49 days of age [61], but that hyperplasia was dominant in rats at the 
ages of 70-77 days old [60].  Our current results in Wistar rats suggest a 
resolution to our previous two conflicting sets of data in that both of our previous 
papers are correct.  The juvenile age of growth when WL takes place affects 
adipose tissue response.  WL effects are essentially masked in younger rats, but 
we see increased cell size from 49 to 56 days regardless if the rats continue 
running (49d RUN < 56d RUN) or undergo WL (49d RUN < 56d WL), suggesting 
that hypertrophy is occurring regardless of physical activity levels.  However in 
70-77 day old rats, WL increased adipocyte number, suggesting a hyperplasic 
response. 
 
Disconnect between decreased food intake and increased adiposity 
The rapid decreased appetite within the first 3 days of WL merits comment 
(Fig. 2.5B), as this is not the first time we have reported this decrease in WL 
experiments in lean rats [60]. The common view is that reduced caloric intake 
would lower fat storage.  Instead, we report that food intake reduction was 
associated with gain in body fat when there is decreased physical activity, 
implying decreased energy expenditure.  Thus, a remarkable disconnect exists 
with common dogma that a reduction in caloric intake reduces body fat.  Physical 
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activity must be factored into this equation, but the caloric cost of reduced 
physical activity can only be assumed, making this a limitation to this 
interpretation.  Interestingly, we observed an initial increase in feed efficiency on 
the first day of WL that was immediately followed by a lower value on the 2nd 
through 6th WL day.  This phenomenon has been observed in other weight gain 
studies, [119] and suggests a lower energetic cost of weight gain during the initial 
days of WL. A new question is thus raised as to whether regulatory mechanisms 
exist to rapidly lower food intake and alter feed efficiency when physical activity is 
decreased.   
Regulatory mechanisms responsible for increased fat gain with both 
decreased caloric intakes and expenditures in lean rats have not been intensely 
examined.  One possible consideration might be related to juvenile rats with 
chronic voluntary running having lower % body fat, which we speculate would 
lower blood leptin and increase leptin sensitivity to inhibit appetite once running 
stopped.  Our speculation is based upon a report by Patterson et al. [120], in 
which 3 wks of voluntary running was associated with increased sensitivity to the 
anorectic effects of leptin without changes in plasma leptin.  We did not measure 
leptin in these rats, so this question remains to be answered.  The immediate 
loss of voluntary running also initiated a spike in food efficiency on the first day of 
WL, which returned down to its pre-WL level on the second WL day. This 
phenomenon has been observed in other weight gain studies [119], and 
suggests a lower energetic cost of weight gain during the initial days of WL.  
MacLean et al. [119] have hypothesized that this initial reduced cost of weight 
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gain in re-feeding after caloric restriction is due to preferential fuel utilization 
shifts towards carbohydrate oxidation and lipid storage in adipose tissue [121].  
Hence, it would be of future interest to delineate mechanisms by which WL may 
be affecting feed efficiency.  Likewise, it would be worthwhile to research how 
energy expenditure prior to and after WL affects appetite altogether.  
Notwithstanding, our data supports Blundell et al. [122]  who suggest that energy 
expenditure can be added to the list of factors regulating energy intake and 
appetite control, and continues to provide compelling evidence suggesting that a 
swift increase in adiposity occurs during the onset of inactivity despite decreases 
in food intake.     
 
Limitations of the study 
There are other iterations of WL that could be performed to further 
understand visceral adipose expansion with WL.  For example, to determine if 
the factor inducing hyperplasic visceral expansion is age or duration of running, 
we could employ a group that gains access to a voluntary running wheel for three 
weeks from 49 to 70 days of age, and is wheel locked from 70 to 77 days of age.  
This group would be age matched with the 70-77 day old rats that had six weeks 
access to a voluntary running wheel.  If the group with access for only three 
weeks showed hyperplasic visceral expansion, then we gain more support to our 
conclusion.  However, if the group with access for only three weeks showed 
hypertrophic visceral expansion, then the duration of voluntary wheel running 
must be considered as a factor in the type of visceral adipose expansion. 
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In conclusion, a rodent model for childhood developmental changes in 
adipose tissue was investigated after one week of greatly reduced daily physical 
activity (7d-WL).  We found that: 1) more robust changes with WL were observed 
in the 70-77 day old rats than in the 49-56 day old rats.  Compared to 77d RUN 
rats, 77d 7d-WL rats exhibited greater rates of gain of fat mass and % body fat, 
increased adipocyte number, higher percentage of small adipocytes, and greater 
cyclin A1 mRNA expression in epididymal and perirenal adipose tissue.  In 
contrast, 49-56 day old rats had no change in most of the same characteristics.  
2) In both age groups, WL did not increase inflammatory mRNA expression.  3) 
There was a disconnect between decreased food intake and increased adiposity, 
suggesting that reduced caloric intake does not reduce body fat when energy 
expenditure is reduced simultaneously. 
From observations in this study, we now present a new hypothesis in 
Chapter 3 that visceral adipose tissue, specifically EAT and PRAT, is expanding 
by hyperplasia in this rat model due to an increase in cell cycle, proliferation, and 
differentiation induced by WL.   
 
Perspective and Significance 
In the context of the current childhood obesity epidemic, there is an urgent 
need to understand underlying mechanisms of adipose tissue growth and 
investigate obesity-prevention strategies.  Since no single tissue or factor can be 
fully responsible for weight regain, the wheel lock model provides a unique 
environment to study how a sudden cessation of daily physical activity affects 
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some characteristics of adipose tissue in pre-pubertal rats.  One alternating 
period of physical activity and inactivity had consequential effects on adipose cell 
number in the EAT and PRAT depots of 70-77 day old rats.  As human childhood 
usually consists of multiple intervals of activity-inactivity, the pre-clinical 
consequences of repeated periods of activity with inactivity should be further 
investigated with invasive approaches using said animal models. 
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CHAPTER 3 
 
 
 
 
STUDY 2: 
 
GLUCOCORTICOID RECEPTOR BLOCKER RU486 ATTENUATES FAT 
GAINS INDUCED BY A SUDDEN DECREASE IN PHYSICAL ACTIVITY, BUT 
BY DIFFERENT PATHWAYS THAN PHYSICAL ACTIVITY 
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ABSTRACT 
 
Voluntary running and glucocorticoids block adipose tissue expansion.  
Young rats that undergo a sudden decrease in daily physical activity [wheel lock 
(WL)] at 70-77 days of age exhibit visceral adipose tissue expansion by 
hyperplasia.  We questioned whether blocking glucocorticoid action would 
attenuate visceral adipose tissue expansion during WL as running attenuates 
visceral adipose expansion.  We tested the hypothesis that similar changes in 
perirenal adipose tissue (PRAT) transcript expression involved in cell cycle, 
proliferation, and differentiation would occur in rats that have access to a 
voluntary running wheel (RUN) and rats that undergo wheel lock plus 
administration of a glucocorticoid receptor block (WL+GR BLOCK) when 
compared to WL rats.  RNA-sequencing (RNA-seq) was performed on PRAT on 
173 transcripts specific to cell cycle, proliferation, and differentiation. RUN and 
WL+GR BLOCK showed no differences in change in fat mass or change in % 
body fat from 70-77 days of age, or differences in PRAT mass at 77 days.  RNA-
seq analysis of the 173 transcripts showed 71 differentially expressed transcripts 
(DETs) between RUN and WL, but only 20 DETs between WL+GR BLOCK and 
WL. Uniquely up- and down-regulated transcripts were identified.  We conclude 
that RUN and WL+GC BLOCK did not affect cell cycle, proliferation, and 
differentiation in the same manner.  The data provide novel insight that two 
different molecular mechanisms block adipose expansion, and stresses the 
importance that a drug does not fully mimic physical activity. 
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INTRODUCTION 
The previous chapter highlighted the growing crisis in public health as 
children become less physically active, coinciding with increased adiposity and 
physical activity during adolescent years [123].   Wheel lock (WL) induces a 
hyperplasic adiposity rebound in epididymal adipose tissue (EAT) and perirenal 
adipose tissue (PRAT) depots.  The mechanism behind this phenomenon is still 
unknown.  The explanation may be as simple as maintaining a high caloric intake 
(positive caloric balance) with a decrease in activity, but the previous chapter 
showed that rats compensate by decreasing food intake within three days after 
WL.   Or the explanation may be more complicated.   
Glucocorticoids (GCs) are of particular interest due to the role they play in 
adipose tissue homeostasis and that glucocorticoid receptor blockers (GR 
BLOCK) have been effectively used to stop fat deposition [88].  Given the 
seriousness of the childhood obesity problem, mechanisms by which we can 
attenuate fat gains with a sudden decrease in activity may be elucidated by a 
comparison of GR BLOCK and WL.  The primary aim of this study was to 
determine whether a GR block attenuates fat gains seen with WL in a similar 
manner as running does.    
GCs (cortisol in humans and corticosterone in rodents) are steroid 
hormones released from the adrenal glands that are important in times of 
physiological or psychological stress [124] and have catabolic effects on lipid and 
protein metabolism with anabolic effects on glycogen storage [76, 125].  GCs 
bind the glucocorcoidoid receptor (GR), which then acts as a transactivator or 
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transrepressor.  While the role of GCs in liver and skeletal muscle is relatively 
clearly defined, the role of GCs in adipose tissue is controversial.  GCs are most 
commonly believed to be lipolytic [76] and increase the amount of energy 
substrates in the blood during energy deprivation [124], but GCs also promote 
preadipocyte differentiation and adipogenesis [77].  GC treatment in children for 
conditions such as asthma and rheumatic diseases, inhibit weight-loss efforts 
and aggravate weight gain [85-87].  GCs are regulated by the enzymes 11-beta 
hydroxysteroid dehydrogenase type 1 (11HSD-1, highly expressed in adipose 
tissue) and type 2 (11HSD-2, highly expressed in the kidney).  11HSD-1 
functions predominately to activate glucocorticoids, while 11HSD-2 primarily 
inactivates glucocorticoids [126].   Interestingly, in animal models when 11HSD-
1 is reduced (thus decreasing tissue exposure to active GC), adipose tissue is 
redistributed towards subcutaneous fat, and animals show improved metabolic 
and blood lipid profiles [127-129]. 
GRs are more highly expressed in visceral fat (VAT) than other fat depots 
[78], and GCs impair insulin sensitivity in adipocytes and promote free fatty acid 
release through hormone sensitive lipase [130].  Further, increased exposure to 
GCs in insulin-sensitive tissues is associated with lipid accumulation and 
metabolic complications [79-83].  Interestingly, GCs affect different fat depots 
differently; they increase lipolysis in peripheral fat depots, like subcutaneous 
adipose tissue (SAT), but they promote pre-adipocyte differentiation and 
adipocyte hypertrophy in VAT [131], so there is something unique to VAT 
regarding GC action.   
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Protection against weight gain, decreased body fat, and a healthier 
adipose tissue phenotype are among the long list of benefits that physical activity 
has on physiology  [66, 67].  Chronic physical activity like endurance training also 
makes tissue more sensitive to GCs, and increases lipolysis in adipose tissue 
[73].  While this provides a valuable energy source for exercising animals, it 
could be detrimental for sedentary animals though increased plasma lipids and 
adipose tissue redistribution towards the viscera [74, 75].   
Mifepristone, or RU486, is a synthetic steroid that acts as an antagonist at 
progesterone and glucocorticoid receptors [132].  RU486 is commonly used for 
termination of pregnancy and emergency contraception, but is also used in 
treatment of burns, and Cushing’s syndrome [132].  In addition to these roles 
RU486 has a potential role in obesity-related disorders like diabetes and 
hypertension by indirectly affecting adipose tissue through the anti-glucocorticoid 
effect [88, 133-135].   
 Few transcriptome-scale studies have been performed on adipose tissue 
and none have been performed on adipose tissue in the context of WL or GR 
block and physical activity.  RNA sequencing (RNA-seq) is a highly reproducible, 
sensitive technique that allows us to observe an entire transcriptome [136].  In 
this study, we performed RNA-seq to investigate quantitative and qualitative 
transcriptome signatures of PRAT from rats that had uninterrupted access to 
voluntary running wheels (RUN), WL, and WL plus GR block (WL+GR BLOCK).   
Prior to RNA-seq analysis, we observed that WL+GR BLOCK rats 
maintained similar levels of adiposity as RUN rats.  Specifically, RUN = WL+GR 
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BLOCK < WL occurred in the following measurements: change in body fat%, 
change in fat mass, PRAT depot mass, and Cyclin A1 mRNA expression, and 
RUN=WL+BLOCK occurred in PRAT adipocyte diameter.  The perirenal fat 
depot was selected for RNA-seq analysis because it is representative of visceral 
fat, is a major adipose target of GC action [137], and exhibited dynamic changes 
in a previous study (Chapter 2). 
Based on this preliminary data and data from other studies [[60] and 
Chapter 2], my overall hypothesis for this study is that, when compared to WL, 
RUN and WL+GR BLOCK would show similar changes in PRAT transcript 
expression involved in cell cycle, proliferation, and differentiation.  
 
 
METHODS 
Animals and Experimental design 
The University of Missouri Animal Care and Use Committee approved 
experimental protocols.  Twenty-four male, Wistar rats were randomly selected 
from a population of Wistar rats bred for high running distances in our laboratory.  
The rats were weaned at 21 days of age and housed as a litter in a single cage.  
At 28 days of age, rats were relocated to a cage equipped with a voluntary 
running wheel and a Sigma Sport BC 800 bicycle computer (Cherry Creek 
Cyclery, Foster Falls, VA) where they were individually housed for the remainder 
of the experiment (Fig. 3.1).  Rats were randomly selected to be in one of four 
groups for the (RUN, WL, WL+GR BLOCK, and WL+VEHICLE, n=6 per group).   
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RUN rats had access to a voluntary running wheel from 28 days of age 
through 77 days of age.  WL, WL+GR BLOCK and WL+VEHICLE rats had 
access to a voluntary running wheel from 28 days of age through 70 days of age, 
when the wheel was locked for the last 7 days.  In addition to WL, WL+GR 
BLOCK and WL+VEHICLE rats received an injection of either DMSO plus 
20mg/kg RU486 (WL+GR BLOCK), which was diluted to a volume of  ~0.5 ml per 
injection, or 0.5 ml DMSO (WL+VEHICLE) once daily at 17.00h (2 hrs prior to the 
dark, physically active 12-hr period).  This dosage was chosen based on 
previous RU486 rat studies [138].  The time was chosen based on the circadian 
rhythm of cortisone; in rats, the level of corticosterone is highest just before 
waking [139] (rats are nocturnal and wake at 19.00h).   
All rats were maintained on a 12-h light (07.00h-19.00h), 12-h dark (19.00-
7.00h) cycle and housed in the same temperature-controlled animal room (21°C).  
All rats had ad labium access to water and standard rodent chow (Formulab 
5008, Purina Mills, St. Louis, MO, USA). Running activity was recorded daily and 
was determined by time and distance ran during the previous 24 hours.  Animal 
cages were exchanged with clean cages every 7 days at which time weekly food 
intake and body weight were recorded.  Rats from the RUN and WL groups are a 
randomly selected subset of rats that were used for the experiment in Chapter 2.  
Rats in the WL+GR BLOCK and WL+VEHICLE groups are unique to this 
experiment.  Rats were family-matched as best as possible; when a litter of at 
least 4 males was available, one rat was assigned to each group.   
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Figure 3.1.  Experimental Design  
Experimental groups are named by the treatment.  All rats began running at the same age (28 days of age), 
underwent treatment at the same age (70 days of age), and were sacrificed at the same age (77 days of 
age).  Light gray bars represent access to a voluntary running wheel, while black bars represent wheel-lock, 
where the rats were housed in the same cage as previously, but the running wheel did not turn (was locked).  
RUN rats had access to a voluntary running wheel for 7 weeks.  WL rats had access to a voluntary running 
wheel for 6 weeks followed by wheel-lock for 1 week.  WL+GR BLOCK rats had access to a voluntary 
running wheel for 6 weeks followed by wheel-lock plus a ~0.5 ml (adjusted to accommodate the correct 
dosage) IP injection of RU486 in DMSO daily (20 mg/kg).  WL+VEHICLE rats had access to a voluntary 
running wheel for 6 weeks followed by wheel-lock plus 0.5 ml IP injection of DMSO daily.  The day that rats 
underwent treatment (70 days of age), they were DXA scanned and weighted.  The day of sacrifice (77 days 
of age), the rats were DXA scanned, weighed, blood was drawn for plasma analysis, and fat pads were 
removed for phenotyping and RNA analysis.    
 
Body composition analysis using DXA 
 At 70 and 77 days of age, body composition was measured between 
10.00h and 12.00h using a dual-energy X-ray absorptiometry (DXA) machine 
calibrated for rats (QDR 4500A, Hologic, Inc. Bedford, MA).  The DXA scan at 70 
days was performed after anesthetization by isofluorine.  At 77 days of age, the 
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DXA scan was performed after CO2 asphyxiation and immediately prior to tissue 
removal. 
 
Animal Sacrifice and tissue collection 
 Rats were terminated by CO2 asphyxiation between 10.00-12.00h, 
weighed, and DXA scanned as described previously.  Four adipose pads were 
removed: omental adipose tissue (OMAT), epididymal adipose tissue (EAT), 
perirenal adipose tissue (PRAT), and subcutaneous adipose tissue (SAT).  
OMAT, EAT, and PRAT depots were completely removed and weighed, while 
only a portion of umbilical/groin SAT was collected.  A sample of OMAT, EAT, 
and PRAT was used for adipocyte sizing (described below), and a sample of 
each of the four fat depots was snap-frozen in liquid nitrogen and stored at -80°C 
for analysis.   Blood was drawn via a cardiac puncture (needle and syringe) for 
plasma analysis.    
 
Adipocyte sizing and number 
On the day of sacrifice, three 60-80 mg fresh adipose tissue fragments 
from OMAT, EAT, and PRAT were weighed and placed in a glass scintillation 
tube with 3 ml Krebs-Ringer-HEPES buffer (KRBH; 130 mM NaCl, 4.7 mM KCl, 
1.2 mM KH2PO4, 10 mM HEPES, 1 mM CaCL2, 1.2 mM MgSO4, 0.25 mg/ml free 
fatty acid-free BSA, pH = 7.4).  Fragments were minced into ~1mm3 pieces, 
incubated with 0.920 Wunsch units of Liberase Blendzyme (Roche) in a 37oC 
incubator at 100 rpm for 1 hour, transferred through a sterile 200 µm nylon mesh 
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(Sefar America, Kansas City, MO) into a 15 ml conical, and centrifuged at 100 
rpm for 1 minute to allow adipocytes to loosely pack at the top of the liquid.  The 
bottom layer of liquid was removed using a syringe and needle and the 
adipocytes were washed with ~5 ml KRBH and resuspended in 5 ml KRBH for 
every 1 ml of loosely packed adipocytes.  A random sample of adipocytes was 
viewed with a Nikon Eclipse E600 microscope and photographed by an Olympus 
DP72 camera.  The diameter of >300 adipocytes was measured using DP2-BSW 
v2.1 software.  The mean diameter and size distribution were calculated for each 
adipocyte depot.   
The number of adipocytes per depot was estimated from the following 
calculation:  the average cell mass was calculated by: average cell size (pl) x 
0.915 (ng lipid/1 pl) x g/109 ng; the number of cells per depot was calculated as:  
mass of adipose depot (g) / average mass of adipocyte (g).  Reliability of this 
method is described in detail [119] and has been used by others [101]. 
 
Corticosterone plasma assay 
Blood plasma was collected by withdrawing blood with a heart stick 
(needle and syringe) and placing the blood in a plasma separating tube.  After 30 
minutes at room temperature, the blood was centrifuged for 10 minutes at 1300 x 
g, and the plasma fraction separated to the top layer.  Plasma was pipetted from 
the tube and placed in a sterile 1.5 ml tube.  Corticosterone levels were 
measured from commercially available corticosterone ELISA kit (Abcam, 
Cambridge, MA) according to the manufacturer’s instructions.  
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RNA isolation for RNA sequencing 
The perirenal fat depot was selected for RNA-seq analysis because it is 
representative of visceral fat, is a major adipose target of GC action [137], and 
exhibited dynamic increases in size in a previous study (Chapter 2). 
Approximately 100 mg of frozen PRAT was homogenized in 1 ml RNA 
lysis buffer (Tri Reagent, Sigma, St. Louis, MO) and a stainless steel bead using 
a high-speed shaking device at 30Hz for 1 min (Tissuelyser LT, Qiagen, 
Valencia, CA).   RNA was isolated using manufacturer’s instructions (Tri 
Reagent, Sigma, St. Louis, MO).  RNA integrity was checked using BioAnalyzer 
2100 (Agilent Technologies Inc., Santa Clara, CA) automated electrophoresis 
system (Bio-Rad, Hercules, CA) prior to cDNA library construction at the 
University of Missouri DNA Core.   
The cDNA library was constructed at the University of Missouri DNA Core 
using manufacturer’s protocol with reagents from Illumina’s TruSeq RNA sample 
preparation kit v2 (Illumina, San Diego, CA).  Briefly, 1) the poly-A containing 
mRNA was purified from total RNA.  2) RNA was fragmented.  3) cDNA was 
generated from this fragmented RNA.  4) sample identifier adapters were ligated 
to the ends.  5) the final constructs were evaluated using the BioAnalyzer 2100 
automated electrophoresis system.  6) these constructs were quantified with the 
Qubit fluorometer (Invitrogen, Carlsbad, CA) using the quant-iT HS dsDNA 
reagent kit (Invitrogen).  7) this was diluted for HiSeq2000 (Illumina, San Diego, 
CA) using Illumina’s standard sequencing protocol.   
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RNA sequencing 
 RNA-seq procedures were performed at the University of Missouri’s DNA 
Core and performed as described elsewhere [140].  Briefly, 1) samples were 
loaded into a flowcell where each olgio was replicated.  2) flowcells were placed 
in the sequencer and fluorescently labeled bases were attached to each 
complementary base.  3) 50 base pair (bp) reads were recorded with the Illumina 
Genome Analyzer (Illumina, San Diego, CA).  4) reads were trimmed to confirm 
adapter sequence removal.  5) reads were tiled to a custom reference using 
NextGEN3 v1.92 software (SoftGenetics, State College, PA).  6) RNA-seq 
sequences for each biological sample were trimmed of adapter and redundant 
sequences.  7) these RNA-seq sequences were aligned to a custom database 
consisting of rat and human homologous sequences using NexGen v2.2 
(SoftGenetics, State College, PA).  Reads per kilobase million (RPKM) values 
were assigned to each transcript.  RPKM is a value that quantifies gene 
expression from RNA sequencing data that normalizes for the number of 
sequencing reads and total read length [141] and is the value that is used to 
compare transcript expression between groups. 
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RNA Sequencing filtering process 
As of now, there is no common standard for RNA-seq analysis, so the 
current RNA-seq literature was examined and a method was devised for a 
filtering process that incorporated aspects of current filtering procedures into the 
dataset.  All analytical procedures were performed with Microsoft Excel v2007 
(Redmond, WA).  To directly address the hypothesis that when compared to WL, 
RUN and WL+GR BLOCK would show similar changes in PRAT transcript 
expression involved in cell cycle, proliferation, and differentiation, a hypothesis-
specific filtering process was employed. The filtering process is described in 
detail and shown in Figure 3.5 in the results section. Briefly, the filtering process 
is as follows:  1) a list of 173 transcripts specific to the hypothesis was generated 
by imputing the term “cell cycle, “’cell cycle’, species ‘R. norvegicus’”, 
“’proliferation’, species ‘R. norvegicus’”, and “’differentiation’, species ‘R. 
norvegicus’” into Gene Ontology Consortium database 
(http://wwwgeneontology.org), as well as searching for genes relevant to cell 
cycle, proliferation, and differentiation in the literature (Table 3.1), 2) three pair-
wise comparisons were performed:  [RUN versus WL], [WL+GR BLOCK versus 
WL], and [RUN versus BLOCK].  [RUN versus WL] and [WL+GR BLOCK versus 
WL] were used for the initial filtering process, while [RUN versus WL+GR 
BLOCK] used as criteria for the final filter) [note: Since the hypothesis was that 
RUN and WL+GR BLOCK would show similar changes in PRAT transcript 
expression, I chose to make WL the control and measure how each of the two 
‘treatments’ (RUN and WL+BR BLOCK) compared to WL.],  3) FILTER #1 – 
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identify significant transcripts: Transcripts were considered significantly different 
if p<0.05, and significant transcripts for the [RUN versus WL] and [WL+GR 
BLOCK versus WL] were identified as up-regulated or down-regulated, 4) 
FILTER #2 – identify transcripts that were “unique to RUN” and “unique to 
WL+GR BLOCK”: transcripts that were identified as commonly up- and down-
regulated between [RUN vs. WL] and [WL+GR BLOCK vs. WL] were omitted, 5) 
from the remaining transcripts, unique transcripts to RUN and to WL+GR BLOCK 
were determined by: a) RPKM ≥ 1 and RUN ≠ WL+GR BLOCK.  Filters were 
chosen based on other RNA-seq literature [136].  
Ingenuity Pathway Analysis (IPA; Ingenuity Systems, Inc., Redwood, CA) 
was used to identify pathways uniquely up- and down-regulated in RUN.  This 
was not performed on BLOCK due to the small number of transcripts that were 
deemed ‘unique.’    
Additionally, to observe the entire PRAT transcriptome without limiting the 
analysis to cell cycle, proliferation, and differentiation transcripts, RNA-seq 
analysis was performed using a second, different filtering process.  Our filtering 
process for the entire data set is described next in detail and shown in Figure 3.7 
of the results section.  Briefly, the filtering process is as follows: 1) the unknown 
transcripts were filtered out of the entire list of transcripts.  2) the transcripts from 
all 6 rats in a given group were compared and transcripts that were not present in 
all six rats were omitted.  3) two pair-wise comparisons were performed for [RUN 
vs. WL] and for [WL+GR BLOCK vs. WL].  4) transcripts that were commonly 
expressed in both groups were analyzed and considered significant if they 
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passed three filters:  a) p < 0.005, b) fold change ≥ 1.5, and c) average RPKM ≥ 
1.0.  5) transcripts that were unique to one group but not the other were analyzed 
separately and considered significant if they passed the same three filters as 
previously described.  Filters were chosen based on other RNA-seq literature 
[142-144].   
 
Statistical analysis 
 Outcome measures for between-group comparisons and within-group 
comparisons (body mass, lean mass, fat mass, and body fat %) were analyzed 
with a two-way analysis of variance (group x time). Significant differences are 
noted with lower-case letters in tables and graphs.  Delta measurements (change 
in body weight, lean body mass, fat mass and % body fat) and tissue 
measurements (depot mass, adipocyte diameter, and total adipocyte number) 
were analyzed with a one-way analysis of variance.  Significant main effects (p < 
0.05) were followed up with Fisher LSD post hoc comparisons.  In addition, a t-
test was used to compare WL and WL+VEHICLE to determine if there was a 
vehicle effect.  Sigmaplot 12.0 (San Jose, CA) was used for all statistical 
analyses.  Values are reported as means ± SE, and significance for all tests was 
set at p < 0.05.  Exceptions to these statistical methods are stated in the figure 
legends.  
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RESULTS 
A t-test was performed between [WL vs. WL+VEHICLE] to determine 
whether the vehicle alone had an effect.  WL and WL+VEHICLE showed no 
differences in any anthropometric measurement (Table 3.2 and Table 3.3), 
indicating that the vehicle, DMSO, did not affect these measurements in this 
study.   In addition, a [WL vs. WL+VEHICLE] comparison was performed on 
hypothesis-specific transcripts (Table 3.1) and on all transcripts from the RNA-
seq analysis.  No significantly different transcripts were identified (WL = 
WL+VEHICLE), indicating that the vehicle, DMSO, did not affect the PRAT 
transcriptome. Since the experimental purpose of this experiment was to 
investigate RUN and WL+GR BLOCK compared to WL, and the usage of the 
WL+VEHICLE alone had no effect on WL, WL+VEHICLE was not included in the 
RNA-seq statistical analysis.   
WL showed significantly greater increases in body mass, fat mass, and % 
body fat when compared to RUN and WL+GR BLOCK (Table 3.2).  Interestingly, 
while RUN equaled WL+GR BLOCK measures of adiposity (change in fat mass 
and change in % body fat), RUN was greater than WL+GR BLOCK in increases 
in total body mass and change in lean mass, indicating that not only does the GR 
block attenuate adipose tissue growth, it attenuates increases in lean mass as 
well.  PRAT mass was greatest in WL (WL was greater than RUN, while RUN 
was equal to WL+GR BLOCK), PRAT adipocyte diameter was equal between 
WL and RUN (WL equaled RUN, while run was greater than WL+GR BLOCK). 
Taken together, these data suggest that the mechanisms differed by which RUN 
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and WL+GR BLOCK slow increases in PRAT mass seen with WL.  Compared to 
WL+GR BLOCK, RUN attenuates increase in total adipocytes while not differing 
in adipocyte diameter. 
 
Different letters denote between-group significant differences at p<0.05.  
 
 
A one-way ANOVA was performed on each outcome measure for all four groups.  Different letters denote 
between-group significant differences at p<0.05. 
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Figure 3.2.  Corticosterone levels  
 
There were no differences in corticosterone levels taken at the same time 
of day [139] (Fig. 3.2). Also, RNA-seq showed that the mRNA expression of GR 
was the same in all groups (average RPKM values: RUN = 42.9417 ± 2.2140, 
WL = 41.4198 ± 1.7956, and WL+BLOCK = 44.7859 ± 1.2951).  Together, for the 
measurements tested, group differences for the glucocorticoid system (plasma 
GCs and GR) were not evident.   
 
 
Figure 3.3: Daily food intake over the last 14 days 
The vertical dashed like represents the day of WL.  The WL rats represented in this table are a subset of the 
WL rats from data presented in Chapter 2.  Different letters denote significance among groups at p<0.05. 
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Food intake was similar among groups until 4 days after WL, at which time 
both the WL and WL+GR BLOCK groups ate less than RUN (Fig. 3.3).  
Importantly however, food intakes tended to start falling from their elevated levels 
on WL-day 1, with the decrease accelerating daily to the significant decline on 
WL-day 4 for both WL and WL+GR BLOCK groups.  Other than 6 days post WL, 
the WL and WL+BLOCK rats ate less than the RUN rats.  Since WL+BLOCK rats 
show the same trend in decreased food intake, this response to appetite to 
decreased activity holds true as the sample size enlarges.  Taken together, WL is 
associated with a rapid decrease in appetite, even with GR block, indicating that 
increases in food intake are not responsible for increases in body fat with WL.    
 
 
 
Figure 3.4. PRAT adipocyte size distribution 
Adipocyte diameters were classified in 10-m categories (10: 0.0-9.0 m, 20: 10.0-19.9m, 20: 20.0-
29.9m, etc.) and the percentage of total adipocytes in a sample was plotted for each category.  At least 300 
adipocyte diameters were measured for each tissue sample.  Different letters denote differences among 
groups at each category, p<0.05. 
 
Like 77d 7d-WL data presented in Chapter 2, the adipocyte distribution 
curve for the WL group flattens out when compared to RUN (Fig. 3.4).  
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Interestingly, the WL+GR BLOCK curve shows an intermediate response with 
less ‘flattening’ and more of a leftward shift compared to both WL and RUN. 
There were more adipocytes in the 30.0-39.9 m category in WL+GR BLOCK 
than in RUN suggesting proliferation and differentiation of new adipocytes.    
The aim of the first filter was to determine which transcripts were different 
between [RUN and WL], different between [WL+GR BLOCK vs. WL], and 
different between [RUN vs. WL+GR BLOCK].   The resulting differences for these 
three comparisons are presented next.   
[RUN vs. WL]: 71 transcripts were significantly different at p<0.05, which 
corresponds to 41.0% of the 173 hypothesis-specific transcripts (Fig. 3.5A).  Of 
these, 18 were up-regulated (25.4%), and 53 were down-regulated (74.6%) 
(Table 3.4).  Of note, Cyclin A1 was down-regulated in RUN rats (fold change = -
1.7229, p=0.0016).  This confirms that there are many DETs between RUN and 
WL in addition to Cyclin A1, thus confirming the conclusion from Chapter 2 that 
WL has increased proliferation compared to RUN.  
[WL+GR BLOCK vs. WL]: 20 transcripts were significantly different at 
p<0.05, which corresponds to 11.6% of the 173 hypothesis-specific transcripts 
(Fig. 3.5A).  Of these, 9 were up-regulated (45.0%), and 11 were down-regulated 
(55.0%) (Table3.4). There were 5 transcripts that were up-regulated and 8 
transcripts that were down-regulated in the [RUN versus WL] and the 
[WL+BLOCK versus WL] comparison (Fig. 3.5A). These are noted in Table 3.4.   
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Figure 3.5. Hypothesis-specific RNA-seq results with filtering process to identify transcripts “unique 
to RUN” and “unique to BLOCK”   
A list of 173 transcripts specific to the hypothesis was generated (see methods and Table 3.1).  Three pair-
wise comparisons were performed:  1A, [RUN versus WL]; 1B, [BLOCK versus WL]; and 1C, [RUN versus 
WL+BLOCK].  FILTER #1: transcripts for each of these pair-wise comparisons were considered significant if 
they were different at p < 0.05.  Figure 3.5A: 71 DETs were identified for [RUN versus WL] and 20 DETs 
were identified for [WL+BLOCK versus WL] (Table 3.4).  The 18 up-regulated transcripts from [RUN versus 
WL] were compared to the 9 up-regulated transcripts from [WL+BLOCK versus WL] to identify common up-
regulated transcripts.  Likewise, the 53 down-regulated transcripts from [RUN versus WL] were compared to 
the 11 down-regulated transcripts from [WL+BLOCK versus WL] to identify common down-regulated 
transcripts  FILTER #2: transcripts were omitted if the RPKM ≤ 1 and if RUN = WL+BLOCK.  Figure 3.5B: 79 
DETs were identified for [RUN versus WL+BLOCK]; 12 were up-regulated, and 67 were down-regulated.  
This comparison was used to directly address the hypothesis as well as significance criteria in FILTER #2. 
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[RUN vs. WL+GR BLOCK]: 79 transcripts were significantly different at 
p<0.05, which corresponds to 45.7% of the 173 hypothesis-specific transcripts 
(Fig. 3.5B).  Of these, 12 were up-regulated (15.2%), and 67 were down-
regulated (84.8%) (Table 3.4).    
The aim of the second filter was to determine which hypothesis-specific 
transcripts were uniquely up- and down-regulated to RUN and to BLOCK (Fig. 
3.5). These hypothesis-specific transcripts are presented next. 
   Unique to RUN, up-regulated: of the 18 up-regulated hypothesis-specific 
transcripts, the 5 transcripts that were also up-regulated in the [WL+GR BLOCK 
vs. WL] analysis were omitted.  Of the remaining 13 transcripts, 5 were omitted 
because they were not different from WL+GR BLOCK.   The 8 remaining 
transcript is highlighted in bold in Table 3.4.  These 8 transcripts were entered 
into IPA analysis, and the top up-regulated network is shown in Figure 3.6A.   
Unique to RUN, down-regulated: of the 53 down-regulated hypothesis-
specific transcripts, the 8 transcripts that were also down-regulated in the 
[WL+GR BLOCK vs. WL] analysis were omitted.  Of the remaining 45 transcripts, 
6 were omitted due to the RPKM values ≤ 1, and 11 were omitted because they 
were not different from WL+BLOCK. The 28 remaining transcript is highlighted in 
bold in Table 3.4. These 28 transcripts were entered in IPA analysis, and the top 
down-regulated network is shown in Figure 3.6B.   
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Unique to WL+GR BLOCK, up-regulated: of the 9 up-regulated 
hypothesis-specific transcripts, the 5 transcripts that were also up-regulated in 
the [RUN vs. WL] analysis were omitted.  Of the remaining 4 transcripts, 2 were 
omitted because they were not different from RUN.  The remaining 2 transcripts 
are highlighted in bold in Table 3.4.  
 Unique to WL+GR BLOCK, down-regulated: of the 11 down-regulated 
hypothesis-specific transcripts, the 8 transcripts that were also down-regulated in 
the [RUN vs. WL] analysis were omitted.  Of the remaining 3 transcripts, one was 
omitted because its RPKM value was less than 1, and one was omitted because 
it was not different from RUN.  The remaining transcript is highlighted in bold in 
Table 3.4.  Interestingly, Angptl4 (up-regulated in WL+GR BLOCK), Smc2 and 
Cdk6 (both down-regulated in RUN) were identified as significant transcripts in 
the entire RNA-seq analysis (Fig. 3.7), thus identifying these three transcripts as 
candidates for future hypotheses. 
My a priori hypothesis was not confirmed. When compared to WL, RUN 
and WL+GR BLOCK do not show similar changes in PRAT transcript expression 
involved in cell cycle, proliferation, and differentiation.  Two tests were performed 
that tested my pre-hoc hypothesis (see introduction and Fig. 3.5A & 3.5B).  Test 
1 compared hypothesis-specific transcripts between RUN and WL+GR BLOCK 
and showed that there were 79 DETs (45.7%) between these groups.  Had there 
been zero DETs between these groups, our hypothesis would have been 
confirmed. Test 2 compared hypothesis-specific transcripts between [RUN vs. 
WL] and [WL+GR BLOCK vs. WL] and did not show similar DETs (RUN: 27.8% 
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of up-regulated DETs and 15.1% of down-regulated DETs were common to 
WL+GR BLOCK; WL+GR BLOCK: 55.6% of DETs up-regulated DETs and 
72.7% of down-regulated DETs were common to RUN). Had all of the DETs 
been the same between these comparisons, the hypothesis would have been 
confirmed.   
 
 
 
(Figure 3.6 is continued on the next page) 
A 
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Figure 3.6.  Top scoring up- and down-regulated networks for transcripts unique to RUN  
A: IPA-derived top-scoring network, “Lipid Metabolism, Molecular Transport, Small Molecule Biochemistry” 
(Table 3.4) produced from a list of 8 transcripts uniquely up-regulated in RUN rats.  The red colored nodes 
represent up-regulated genes.  B: IPA-derived top-scoring network, “Cell Cycle, Cell Death and Survival, 
Tumor Morphology” (Table 3.4) produced from a list of 28 transcripts uniquely down-regulated in RUN rats.  
Green colored nodes represent down-regulated genes. 
 
 
 
 
 
 
 
 
 
 
 
B 
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Figure 3.7: Whole transcriptome RNA-seq filtering process and results  
For each group, a transcript was omitted if it was not known and not expressed in each member of that 
group.  There were 16,918 RUN, 17,128 BLOCK, and 17,226 WL+BLOCK transcripts remaining after this.  
Two comparisons were performed:  [RUN versus WL] and [WL+BLOCK versus WL].  For the [RUN versus 
WL] comparison, there were 16,610 commonly expressed genes that were compared and filtered for 
significance.  A transcript was deemed significantly different between RUN and WL if: 1) p<0.005, 2) fold 
change ≥ 1.5, and 3) average RPKM ≥ 1.  117 transcripts met these criteria.  Of these 118 transcripts, 73 
were up-regulated and 44 were down-regulated.  The top-10 transcripts and top IPA network for each are 
listed in Table 3.5.  There were 308 transcripts that were expressed in RUN but not in WL.  Of these, 14 
transcripts had a RPKM ≥ 1.  The top-10 transcripts and top network are listed in Table 3.6.  There were 518 
transcripts that were expressed in WL but not in RUN.  Of these, 25 transcripts had a RPKM ≥ 1.  The top-
10 transcripts and top network are listed in Table 3.6.  For the [WL+BLOCK versus WL] comparison, there 
were 16,784 commonly expressed genes that were compared and filtered for significance using the same 
criteria as described above.  143 transcripts met these criteria.  Of these 143 transcripts, 96 were up-
regulated and 37 were down-regulated.  The top-10 transcripts and top IPA networks for each are listed in 
Table 3.5.  There were 442 transcripts that were expressed in WL+BLOCK but not in WL.  Of these, 27 had 
a RPKM ≥ 1.  The top-10 transcripts and top IPA network are listed in Table 3.6.  There were 334 transcripts 
that were expressed in WL but not in WL+BLOCK.  Of these, 21 had a RPKM ≥ 1.  The top-10 transcripts 
and top IPA network are listed in Table 3.6.  The entire list of transcripts identified in the RUN vs. WL 
comparison can be found in Appendix A. 
  
To observe the entire PRAT transcriptome without limiting the analysis to 
cell cycle, proliferation, and differentiation transcripts, RNA-seq analysis was 
performed using a different filtering process. The rationale for including this data 
here is to show the “wealth” of data that can be analyzed in the future.  Top 
transcripts and pathways are identified in Table 3.5 & 3.6.  
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DISCUSSION  
The primary purpose of this experiment was to determine whether RUN 
and GR block had similar transcriptional profiles for genes involved in cell cycle, 
proliferation, and differentiation.  Based on this preliminary data and data from 
other studies [[60] and Chapter 2], my overall hypothesis for this study is that, 
when compared to WL, RUN and WL+GR BLOCK would show similar changes in 
PRAT transcript expression involved in cell cycle, proliferation, and 
differentiation. I tested this hypothesis two ways: 
1) If a comparison of hypothesis-specific transcripts between RUN and WL+GR 
BLOCK show similar up- and down-regulation, then we can conclude that 
these two conditions express similar transcript changes and probably affect 
cell cycle, proliferation, and differentiation in the same manner. But if there 
are many differentially expressed hypothesis-specific transcripts between 
RUN and WL+GR BLOCK, then we can conclude that these two conditions 
do not affect cell cycle, proliferation, and differentiation in the same manner, 
and RUN and WL+GR BLOCK likely keep fat from accumulating by different 
mechanisms. 
2) If the DETs for the hypothesis-specific genes for the comparison of [RUN vs. 
WL] and the comparison of [WL+BLOCK vs. WL] are the same, then we can 
conclude that these two conditions affect transcripts related to cell cycle, 
proliferation, and differentiation when compared to WL similarly and probably 
work to keep fat from accumulating in the same manner.  But if there are 
many DETs identified for the comparison of [RUN vs. WL] that differ from the 
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comparisons of [WL+BLOCK vs. WL], we can conclude that these two 
conditions do not affect cell cycle, proliferation, and differentiation in the 
same manner and likely keep fat from accumulating by different 
mechanisms.   
If the hypothesis was accepted, then further analysis will be performed on 
the top transcripts that were similarly expressed in RUN and WL+GR BLOCK to 
identify a common pathway involved with suppression of fat accumulation with 
WL and to identify candidate genes for potential future studies.  If the hypothesis 
was not accepted, then the top up-regulated and top down-regulated genes 
unique to RUN (not up/down-regulated in WL+GR BLOCK) and to WL+GR 
BLOCK (not up/down-regulated in RUN) would be identified for analysis on 
potential key transcripts and pathways unique to RUN and to WL+GR BLOCK.  
These unique transcripts could help identify differing mechanisms by which RUN 
and WL+GR BLOCK attenuate the increase in fat with WL.  Additionally, these 
hypothesis-specific transcripts would test the hypothesis presented at the end of 
Chapter 2 that “perirenal adipose tissue is expanding by hyperplasia due to an 
increase in cell cycle, proliferation, and differentiation.”  Finally, RNA-seq data 
from all transcripts was analyzed in order to observe other non-cell cycle, 
proliferation, and differentiation pathway transcriptomic differences within PRAT 
that existed among RUN, WL, and WL+BLOCK in order to generate new 
hypotheses for future experiments using this model.  
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Two separate analyses of transcripts involved in cell cycle, proliferation, 
and differentiation showed that, contrary to the hypothesis, RUN and WL+GR 
BLOCK express different transcripts.  We concluded that these two conditions 
did not affect cell cycle, proliferation, and differentiation in the same manner.  We 
then identified which transcripts differed between RUN and WL+GR BLOCK to 
identify potential key transcripts and pathways unique to RUN and to WL+GR 
BLOCK to generate new hypotheses.  A secondary purpose of this experiment 
was to confirm the findings in Chapter 2 and provide more molecular support that 
WL increases PRAT by increased molecular markers of cell cycle, proliferation, 
and differentiation.  We conclude that indeed, PRAT from WL animals show 
many changes (41.0% of the 173 hypothesis-specific genes differed) in cell 
cycle, proliferation, and differentiation genes when compared to RUN. 
RUN and WL+GR BLOCK groups failed to attain levels of fat mass, % 
body fat, and PRAT depot mass associated with WL.  However WL+GR BLOCK 
also prevented gains in both total body mass and lean body mass, which were 
present in WL and RUN groups.  This is consistent with the literature in that 
RU486 has been shown to attenuate body mass gains in rodents [145] and in 
humans [146]. However, it is interesting that this occurred since increased GC 
levels in skeletal muscle leads to decreased protein synthesis and increased 
proteolysis.  Patients with excess GC often present muscle atrophy and 
weakness [147], and contrary to our findings, in the presence of excessive GCs, 
RU486 prevents muscle atrophy [148]. The rats in this study did not exhibit 
excess cortiosterone and, to our knowledge, were not experiencing GC-induced 
93 
 
muscle atrophy.  WL+GR BLOCK rats had a similar PRAT mean adipocyte 
diameter as RUN, but less than WL.  However, WL+GR BLOCK rats had 
statistically the same estimated number of adipocytes as WL. This observation 
was also present in the adipocyte size distribution curve.  WL+GR BLOCK rats 
did not exhibit a flattening of the curve to the same extent as WL.  Rather, the 
curve was slightly shifted to the left and there were more adipocytes in the 30.0-
39.9 m category in WL+GR BLOCK than in RUN, suggesting that WL+GR 
BLOCK either had proliferation and differentiation of new adipocytes or a lipolysis 
and ‘shrinking’ of pre-existing adipocytes.   Regarding the possibility of increased 
lipolysis in WL+GR BLOCK, enzymes involved in triacylglycerol breakdown 
include adipose triglycerol lipase (AGTL), hormone sensitive lipase (HSL), and 
monoglycerol lipase (MGL) were evaluated from RNA-seq data.  AGTL, HSL, 
and MGL were not different between RUN and WL+GR BLOCK.  However, 
ATGL was up-regulated in [RUN vs. WL] (fold change = 1.3280, p=0.0196) and 
HSL was up-regulated in [WL+GR BLOCK vs. WL] (fold change = 1.2927, 
p=0.043).  The last observation offers some support to the notion of smaller 
adipocytes in WL+GR BLOCK compared to WL due to increased lipolysis. 
We did not see a difference in corticosterone levels in any group.  GCs are 
often discussed in the context of Cushing’s syndrome, where there is an excess 
of circulating GCs with patients presenting with central obesity symptoms similar 
to patients with common metabolic syndrome [149].  Unlike Cushing’s syndrome, 
in common obesity, systemic GC levels do not change [126, 150] and may be 
lower than in lean individuals [151], suggesting that elevated systemic cortisol 
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levels are not the cause of WL-induced increases in abdominal adiposity.  
Interestingly, GCs affect different fat depots differently; they increase lipolysis in 
peripheral fat depots, but they promote pre-adipocyte differentiation and 
adipocyte hypertrophy in VAT [131], so there is something unique to VAT for 
response to GC action.   
Given the important role of the enzyme 11HSD-1 in adipose tissue 
regarding visceral obesity and metabolic health (see Chapter 1 and Chapter 4 
and [126, 152-155], it is worth mentioning that WL+GR BLOCK up-regulated 
11HSD-1 compared to RUN (1.4031, p= 0.025) and compared to WL (fold 
change = 1.4627, p = 0.034).  Expression in RUN did not differ from WL (fold 
change = 1.0425, p = 0.749).  Interestingly, 11HSD-2 was the top down-
regulated transcript identified between [WL vs. WL+GR BLOCK] (fold change = -
3.6637, p = 0.00002).  In the context of RUN versus WL, the fact that the 
expression of neither of these isoforms differed indicates that this GC-
activating/inactivation pathway is not critical to adipose tissue homeostasis in our 
model.  However, when GC action is attenuated, such as with the GR block, the 
up-regulation of 11HSD-1 may indicate that 11HSD-1 acts as a compensatory 
mechanism to increase GC activity in PRAT.  
 
RNA-sequencing  
The remainder of the discussion will address RNA-seq analysis on 
transcripts specific to the pre-hoc hypothesis, specifically particular transcripts 
that were unique to RUN and to WL+GR BLOCK (Fig. 3.5 and Table 3.4), with 
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hopes that these transcripts will provide insight into the differing mechanisms by 
which RUN and WL+BR BLOCK attenuate fat gains seen with WL.  Speculation 
and discussion on transcripts identified in the entire RNA-seq analysis (Fig. 3.7) 
is not presented here.  The purpose of showing data from the entire RNA-seq 
transcriptome in the results section was to show that there are additional 
transcripts and pathways that can be addressed from this RNA-seq dataset in 
future studies.   
Previous RNA Sequencing studies categorized gene expression levels 
into three groups: “low expressed transcripts” are between 0.125-0.999 RPKM 
average, “medium expressed transcripts” are between 1.0 and 10.0 RPKM 
average, and “high expressed transcripts” are above 10.0 RPKM average [142].  
All transcripts classified as “low expressed” were omitted in the filtering process.  
The rationale for this decision was that transcripts expressed between 1.0-3.0 
RPKM are equivalent to a single gene copy per cell [141].  If a transcript is 
expressed at a level less than one per cell, it is questionable if the transcript 
actually exerts an effect.  The RPKM values for transcripts discussed below are 
provided, thus allowing speculation to the potential magnitude of these 
transcripts.  Overall, my interpretation of the following findings are that RUN 
limited cell cycle progression, proliferation, and differentiation compared to 
WL+GR BLOCK rats. 
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Transcripts unique to RUN.   
There were 8 transcripts unique to RUN that were up-regulated and 28 
transcripts unique to RUN that were down-regulated.  These transcripts were 
entered into an IPA analysis and the top pathways were identified.  A limitation of 
IPA is that pathway names are IPA’s and sometimes their names are broader 
than our data.  The unique transcripts for both up- and down-regulation will be 
discussed in the context of the top pathway for both up- and down-regulation.  In 
addition to the transcripts in the top down-regulated pathway, two additional 
interesting down-regulated transcripts will be discussed.    
 
Transcripts uniquely up-regulated in RUN. 
IPA analysis identified “Lipid Metabolism, Molecular Transport, Small 
Molecule Biochemistry” as the top pathway given, which happened to include all 
8 transcripts: diacylglycerol O-acyltransferase 1 (Dgat1), diacylglycerol O-
acyltransferase 2 (Dgat2), protein kinase, cAMP-dependent, regulatory, type II, 
beta (Prkar2b), signal transducer and activator of transcription 5a (Stat5a), cell 
division cycle 34 homolog (Cdc34), cell division cycle 123 homolog (Cdc123), 
phosphoglucomutase 1 (Pgm1), and mitogen-activated protein kinase 6 (Mapk6) 
(Fig. 3.6A).   
Dgat1 and Dgat 2 (diacylglycerol O-acyltransferase 1 and 2) are highly 
expressed in PRAT (RPKM average = 117.1175 and 854.678, respectively, 
n=24) and mRNA expression has been shown to be down-regulated in the 
presence of an active-GC suppressor [156], suggesting that Dgat expression is 
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regulated by GCs.  DGATs catalyzes the final reaction of triglyceride synthesis 
and is a characteristic of a fully differentiated adipocyte.  In fact, overexpression 
of Dgat1 reduces cell growth rate and proliferation [157], while Dgat1 knock-out 
mice are resistant to obesity [158], have increased sensitivity to insulin and 
leptin, and are resistant to diet-induced hepatic steatosis [159]. Dgat1 mRNA 
expression increases in skeletal muscle of mice and humans after an acute bout 
of exercise yet is unchanged after chronic exercise training [160], but there is no 
previous data to our knowledge on adipose tissue and exercise.  Dgat2 has been 
shown by others to increase in the absence of Dgat1.  Dgat2 knock-out mice are 
lipopenic and do not survive [158], suggesting that, unlike Dgat1, Dgat2 is more 
critical in adipose tissue.  While it may seem strange that transcripts that encode 
proteins involved in triglyceride synthesis are up-regulated in rats that do not gain 
body weight, it should not be surprising since expression of Dgat1 and Dgat2 are 
influenced by GCs.  Most likely, Dgat1 and Dgat2 expression are down-regulated 
in PRAT due to GR block rather than up-regulated by running.  Still, the Dgat 
data indicates that there is more triglyceride synthesis occurring in RUN rats than 
in WL+GR BLOCK rats, and RUN rats had higher expression of both Dgats 
compared to WL (Dgat1 fold change = 1.4662, p = 0.00008; Dgat2 fold change = 
1.4943, p = 0.494).  One possible explanation is that Dgats are up-regulated in 
RUN rats vs WL+GR BLOCK rats because stored triglyceride is more 
metabolically active in RUN PRAT and turns over constantly, allowing adipose 
tissue to readily respond to changes in energy balance [161]. This also supports 
a second explanation in that the less expression of Dgats in WL+GR BLOCK 
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would account for, or be a reflection of, lack of accumulation of TG in adipose 
tissue.  Still, the fact that the RUN rats are not showing a net accumulation of 
adipose tissue makes the Dgat up-regulation perplexing.  The mRNA expression 
may not reflect a physiological outcome as a >20-fold increase in Dgat1 mRNA 
resulted in only a 2-fold increase in protein expression and function [162].   
Prkar2b ( protein kinase, cAMP-dependent, regulatory, type II beta) and 
Stat5a (signal transducer and activator of transcription 5a) are both highly 
expressed in all groups’ PRAT (PRAT RPKM average = 223.6515 and 11.8084, 
respectively, n=24).  Prkar2b is involved in lipolysis and plays a crucial and 
central role in the regulation of energy expenditure and glucose and lipid 
metabolism [163, 164] and proliferation of ovarian cells [165], so Prkar2b could 
contribute to the suspected increased triacylglycerol turnover.  Stat5a is activated 
by GR [166] and shows increased activity during differentiation and adipogenesis 
[167-169]. KO of either of these transcripts in mice show decreased adiposity 
[170]. Our interpretation of the findings is that the previous four transcripts 
(Dgat1, Dgat2, Prkar2b and Stat5a) all seem to go the ‘wrong’ way given that the 
RUN rats did not accumulate fat.  We suggest as an alternative interpretation, if 
these four transcripts are thought of as being “lower in WL+GR BLOCK rats,” 
then the 1.5-fold up-regulation in RUN is not surprising.  Dgat1, Dgat2, and 
Stat5a are all influenced by GC and/or GR activity, which would potentially 
decrease their expression. Also, in WL+GR BLOCK rats, lipid accumulation was 
attenuated (smaller adipocytes) when compared to RUN.   
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Cdc34 (cell division cycle 34 homolog) is highly expressed in all groups’ 
PRAT (PRAT RPKM average = 20.7496, n=24).  Cdc34 encodes an ubiquitin 
conjugating enzyme [171].  Overexpression of this enzyme enhances the 
ubiquitin proteasome system and promotes degradation of proteins [172].  Notice 
that ubiquitin C (UBC) is at the hub of this pathway analysis (Fig. 3.6A: top up-
regulated pathway in RUN).   The ubiquitin-proteasome system controls spatial 
and temporal cellular processes like cell proliferation and cell death [173].  If this 
occurs in RUN adipocytes, Cdc34 up-regulation may be enhancing the 
ubiquination of other transcripts in this pathway shown in Figure 3.6A.  Increased 
transcription would lead to increased mRNA, which would necessitate increased 
degradation.   
Cdc123 (cell division cycle 123) is highly expressed in all groups’ PRAT 
(PRAT RPKM average = 468739, n=24).  Cdc123 encodes a protein involved in 
cell cycle regulation and is regulated by nutrient availability [174]. 
Overexpression of Cdc123 causes cell cycle delay [174].  Mapk6 (mitogen-
activated protein kinase 6, also referred to as Erk3) is highly expressed in PRAT 
(PRAT RPKM average = 19.1414, n=24).  Mapk6 is a signaling molecule 
involved in cell-cycle progression and cell differentiation and protein levels are 
up-regulated during cell-cycle and terminal differentiation [175].  To sum up, an 
up-regulation of Cdc123 and Mapk6 in RUN rats may indicate a decrease in cell 
cycle progression and may help explain a role in the attenuation of total 
adipocyte number in RUN compared to WL and BLOCK. 
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Taken together, the uniquely up-regulated transcripts in RUN indicate that 
there is an increase transcripts involved with triglyceride accumulation and an 
increase in transcripts involved with inhibiting cell cycle progression when 
compared to WL+GR BLOCK.  This fits with our findings that RUN rats have 
fewer PRAT adipocytes despite similar PRAT depot mass. 
 
Transcripts uniquely down-regulated in RUN. 
IPA analysis identified “Cell Cycle, Cell Death and Survival, Tumor 
Morphology” as the top down-regulated pathway, which included 12 of the 28 
uniquely down-regulated transcripts for RUN (Fig. 3.6B).  Further analysis of 
these 12 transcripts revealed that 6 of the 12 [cell division cycle 6 homolog 
(Cdc6), cell division cycle 14 homolog B (Cdc14b), cell division cycle 25 homolog 
C (Cdc25c), cyclin-dependent kinase 1 (Cdk1), kinesin family member 11 (Kif11), 
and polo-like kinase 1 (Plk1)] were interconnected in that they were all involved 
in the same cell cycle regulation pathway as described next.  Expression levels 
(average RPKM for 24 rats) for the 12 transcripts are: Cdk1: 4.4820, Cdc25b: 
4.7615, Cdc14b: 2.2736, Kif11: 1.3912, Plk1: 1.1734, Cdc6: 1.5155, Cdk6: 
5.6043, Cebpd: 7.8986, Fgf18: 4.2732, Bmp2: 2.7595, Bmp7: 4.2424, and 
Ccna2: 2.3945. 
Cdk1 is a key player in cell cycle regulation [176], and its phosphorylated 
form (inactive) is increased in presence of dexamethasone [177].  The 
Cdk1/cyclin B complex is maintained in an inactive, phosphorylated state.  The 
Cdk1/cyclin B complex is activated through dephosphorlyation by Cdc25b, which 
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promotes entry into and progression through early mitosis [178].  Interestingly, 
Cdc25b is activated by GR [179].  Activated Cdk1/cyclin B initiates a positive 
feedback loop by phosphorylating Cdc25b, thus inactivating it.  Cdc14b can also 
inactivate Cdc25b [180].  Kif11 (Eg5) is involved in the formation of bipolar 
spindle formation, is essential in human cells, and inhibition results in mitotic 
arrest and cell death [181, 182]. Cdk1 can phosphorlyate Kif11, which allows for 
regulation of centrosome separation (8548803).  Plk1 is highly expressed in 
proliferating cells [183] and is one of the proteins that can phosphorylate cyclin 
[184] as well as initiate a cascade that regulates the accumulation of Kif11 [185].  
Cdc6 can be phosphorylated by Cdk1 and Plk1 [186], but Cdc6 can also inhibit 
Cdk1 and lead to an accelerated exit from mitosis [186].  Note that Cyclin B did 
not pass the analysis filters but was down-regulated in RUN compared to WL 
(RUN v WL: fold change = -1.8083, p=0.209) and in RUN compared to WL+GR 
BLOCK (RUN vs. WL+GR BLOCK: fold change = -2.623, p=0.0442).  Taken 
together, it is clear that these six transcripts work together to control, regulate, 
and maintain cell cycle function.  All of these transcripts are down-regulated in 
RUN rats, which indicate that this particular pathway may not be as robust in the 
RUN rats as compared to the WL+GR BLOCK rats.  This molecular data 
supports the observed lower total adipocyte number seen in RUN compared to 
WL+GR BLOCK. 
The other six down-regulated RUN transcripts also play a role in cell cycle, 
proliferation, and differentiation.  Cyclin-dependent kinase 6 (Cdk6) was 
identified as a transcript uniquely down-regulated in RUN, but it was also 
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identified as one of the 42 significantly down-regulated transcripts in the entire 
RNA-seq analysis (Fig. 3.5).  Cdk6 combines with Cdk4 to phosphorylating 
(inactivating) cell cycle inhibitors like pRB [187].  Note that the transcript for pRb 
(Rb1) is down-regulated in WL+GR BLOCK rats (see discussion below).   Down-
regulation of Cdk6 in RUN would ultimately allow pRb to inhibit cell cycle 
(decrease the inactivation an inhibitor of cell cycle). Also note that Cdk4 did not 
pass the analysis filters but had a down-regulated trend in RUN compared to WL 
(fold change = -1.3474, p=0.0715) and in RUN compared to WL+GR BLOCK 
(fold change = -1.1677, p=0.0672).  CCAAT/enhancer binding protein (C/EBP), 
delta.  Cebpd is involved in adipocyte differentiation [188, 189], fibroblast growth 
factor 18 (Fgf18) regulates white AT development and has a regulatory role in 
adipocyte differentiation and FGF18 has been document in WAT [190], bone 
morphogenic protein 2 (Bmp2) induces adipogenic differentiation of 
mesenchymal stem cells [191], and together with bone morphogenic protein 7 
(Bmp7), increase lipid accumulation of 3T3-L1 preadipocytes in the absence of 
the normally required culture media cocktail [192], and cyclin A2 (Ccna2) is 
expressed briefly before Cyclin A1 in the early cell cycle [193].  The fact that all of 
these transcripts are down-regulated in RUN rats suggests that cell cycle activity 
is depressed, and potentially proliferation and differentiation of adipocytes is not 
occurring as rapidly in RUN rats as in WL+GR BLOCK rats.   
Lastly, it is worth mentioning that structural maintenance of chromosomes 
2 (Smc2) was identified as unique to RUN, and it was also identified as one of 
the 42 significantly down-regulated transcripts in the entire RNA-seq analysis 
103 
 
(Fig. 3.5),  but it was not in the top down-regulated IPA pathway.  Smc2 is 
integral to cell cycle progression.  Smc2 joins with Smc4 to form a heterodimer 
and ultimately form condensing, a required protein for sister chromatid cohesion 
and DNA repair [194, 195].  While not on the final list, Smc4 was down-regulated 
in RUN compared to both WL+GR BLOCK (p=0.0087) and WL (p=0.0078) (Table 
3.4). 
Taken together, the uniquely down-regulated transcripts in RUN indicate 
that there is a decrease transcripts involved with promoting cell cycle 
progression, proliferation, and differentiation when compared to WL+GR BLOCK.  
This fits with our findings that RUN rats have fewer PRAT adipocytes despite 
similar PRAT depot mass. 
 
Transcripts unique to WL+GR BLOCK.   
Unlike RUN with 8 unique transcripts up-regulated, in the WL+GR BLOCK 
group there were only two transcripts that were up-regulated and one transcript 
that was down-regulated (Table 3.4), so an IPA analysis of pathways was not 
possible.  Therefore, the three transcripts that are unique to BLOCK will be 
discussed individually. 
Transcripts uniquely up-regulated in WL+GR BLOCK.   
The transcripts for angiopoietin-like 4 (Angptl4) and cell division cycle 73 
(Cdc73) were filtered out of 173 genes as the only two transcripts up-regulated 
uniquely to WL+GR BLOCK.   
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Angptl4 was highly expressed in PRAT (average RPKM = 157.9973, 
n=24), was expressed at higher levels in WL+GR BLOCK compared to WL (fold 
change = 1.775, p=0.0023), and was also expressed at higher levels in WL+GR 
BLOCK than RUN (fold change = 1.742, p=0.0499).  ANGPTL4, one of seven 
secreted ANGPTL proteins, is an adipokine that is predominately expressed in 
adipose tissue and liver and is involved in lipid metabolism [196] and 
triacylglycerol homeostasis [197]. It was originally identified as fasting-induced 
factor from liver [198] and is a downstream target of PPAR and PPAR during 
pre-adipocyte differentiation [199].  Angptl4 has been linked to circulating lipids 
and high density lipoprotein and triglyceride concentrations [200-202] and as a 
lipoprotein lipase (LPL) inhibitor [203, 204].  Since Angpl4 is up-regulated in 
WL+GR BLOCK rats, LPL may be inhibited, which would limit the fat entry into 
adipocytes, thus attenuating fat accumulation.  The Lpl transcript was more 
highly expressed in RUN than in WL+GR BLOCK ([RUN versus WL+GR BLOCK] 
fold change = 1.446, p = 0.0003), indicating that the Angptl4 up-regulation in 
WL+GR BLOCK may be influencing LPL action in these rats.   
Angptl4 expression is induced during adipocyte differentiation and levels 
continue to rise once the adipocyte is fully differentiated [205-207], supporting the 
observation of increased total adipocyte number in WL+GR BLOCK rats.  
ANGPTL4 stimulates the increased activation of c-Jun and Junb both of which 
are transcription factors involved in proliferation [208]. Junb was expressed at 
higher levels in WL+GR BLOCK than RUN (RUN versus WL+GR BLOCK fold 
change = -1.352, p = 0.0422), suggesting that a downstream target of Angptl4 
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that is involved in cell proliferation is increased in WL+GR BLOCK rats, providing 
further molecular support of increased total adipocyte number in WL+GR BLOCK 
rats.  
Our finding that Angptl4 expression is higher with GR block is puzzling 
since GR is a transcription factor for Angptl4 [209].  In a fasting-induced Angptl4 
model, GR blockade by RU486 prevented increased Angptl4 expression in liver 
white epididymal adipose tissue in mice [209], but this appears to be limited to 
fasting-induced models [197] as the GR blockade did not prevent an change in 
Angptl4 mRNA levels when the animals were fed ad libitum, only when they were 
fasted.  There are other transcription factors for Angptl4 including PPAR [205, 
207], and PPAR has been shown to reverse effects of GC inhibition [210].  In 
the WL+GR BLOCK animals, the Pparg transcript was highly expressed (RPKM 
= 79.377), suggesting that PPAR may contribute to the Angptl4 up-regulation.  
Cdc73 (Cell division cycle 73) is a medium-expressed transcript (average 
RPKM = 9.2473, n=24), was expressed at higher levels in WL+GR BLOCK 
compared to WL (fold change = 1.190, p = 0.0061), and was also expressed at 
higher levels in WL+GR BLOCK than RUN (fold change = 1.301, p = 0.0092 
Cdc73 one of several members of the polymerase II-associated factor (PaF) 
complex.  No data was found on Cdc73 and adipose tissue, but it plays a role in 
cell proliferation [211] and is involved transcription initiation and elongation and 
mRNA processing [212].  Cdc73 negatively regulates b-catenin, Cyclin D1 and c-
MYC [211], thus acting to inhibit cell cycle,   which supports our findings that 
RUN rats have fewer PRAT adipocytes despite similar PRAT depot mass. 
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Transcript uniquely down-regulated in WL+GR BLOCK. 
The retinoblastoma (Rb1) transcript was filtered out of 173 genes as the 
only gene down-regulated uniquely to WL+GR BLOCK.  Rb1 is a medium-
expressed transcript (RPKM average = 1.7749, n=24 rats) and was expressed at 
lower levels in WL+GR BLOCK compared to WL (fold change = -1.128, p=0.041) 
and was also expressed at lower levels in WL+GR BLOCK than RUN (fold 
change = -1.163, p=0.0132).   
Rb1 transcribes the tumor suppressor protein pRb protein and, when 
dephosphorylated, acts as a negative regulator of the cell cycle.  Interestingly, 
GC have been shown to work through Rb1 dephosphorylation to induce G1 cell 
cycle arrest [213]. Rb1 plays a role in tumor suppression, cell cycle progression, 
apoptosis, and cell differentiation [214-217],  and in adipocytes, Rb1 facilitates 
preadipocyte differentiation into adipocytes [218].  Rb1 is lowly expressed 
(RPKM = 1.579) in PRAT of WL+GR BLOCK rats, but the down-regulation 
indicates that this ‘brake’ on cell cycle is decreased, thus promoting cell cycle 
progression and differentiation.    
The three transcripts discussed above that are unique to WL+GR BLOCK 
provide molecular evidence that transcripts promoting cell cycle progression, cell 
proliferation, and differentiation are present at a higher level in WL+GR BLOCK 
compared to RUN, and a transcript that inhibits cell cycle progression is present 
at lower levels in WL+GR BLOCK compared to RUN.  Taken together, this data 
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supports the observed perirenal adipose phenotype of increased total adipocyte 
number in WL+GR BLOCK rats.  
The unique transcripts that were different between RUN and WL+GR 
BLOCK were investigated because our findings indicated that RUN and WL+GR 
BLOCK used different pathways to attenuate visceral adipose expansion.  
However, given that some of the transcripts were common to RUN and WL+GR 
BLOCK, there is some molecular similarity between the two groups.   
  
 
Confirmation of conclusion from Chapter 2 
RNA-seq analysis of cyclin A1 showed that it was down-regulated in RUN 
rats (fold change = -1.7229, p=0.0016), which confirmed mRNA analysis from 
Chapter 2 that showed Cyclin A1 was down-regulated in RUN rats (fold change = 
-1.5549, p=0.0198).  Further analysis showed that 41.0% of the 173 hypothesis-
specific, cell cycle, proliferation, and differentiation transcripts were different 
between RUN and WL.  A brief review of the 18 transcripts that were up-
regulated in RUN include those involved with triglyceride accumulation and 
inhibition of cell cycle progression, much like when RUN was compared to 
WL+GR BLOCK.   Many of the 53 transcripts that were down-regulated in RUN 
are involved in cell cycle progression, proliferation, and differentiation. This 
confirmed that there are many DETs between RUN and WL in addition to cyclin 
A1, thus adding to the molecular evidence from Chapter 2 and allowing us to 
hypothesize that a sudden decrease in activity causes an increase in adiposity 
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due to increases incell cycle progression, proliferation, and differentiation of 
preadipocytes.  
 
 
Limitations of the study 
A limitation of study was that there was not a RUN+GR BLOCK group.  
Without this group, we cannot fully determine the effects of RU486 in conjunction 
with activity (RUN+BR BLOCK).  In other words, would have RU486 negated the 
effects of RUN, and caused an increase in transcripts involved with cell cycle 
progression, proliferation, and differentiation as was observed in the WL+GR 
BLOCK group?  Future studies can be designed to address these hypotheses 
and limitations.   In defense of not having a RUN+GR BLOCK group, the way the 
hypothesis was stated looked at 1) how does RUN attenuate PRAT gains seen 
with WL?  2) how does WL+GR BLOCK attenuate PRAT gains seen with WL? 
and 3) does RUN and WL+GR BLOCK do this the same way?  In this regard, a 
RUN+GR BLOCK was not necessary.   
Another limitation is that we did not block GR specifically in PRAT.  
Instead we had a systemic GR block.  This calls into question the effect that 
other GC target tissues such as liver and skeletal muscle and kidney had on 
adipose tissue.  Given the interconnectedness, it would be unlikely that the effect 
we saw in PRAT is limited to adipose physiology.   It is more likely that it was the 
interplay of altered liver, skeletal muscle, and kidney function that contributed to 
109 
 
the effect we saw in PRAT.  To address this, an osmotic pump or other device to 
locally administer a drug could be used to isolate GR block specifically to PRAT. 
In conclusion, we found that RUN and WL+GC BLOCK did NOT affect cell 
cycle, proliferation, and differentiation in the same manner.  We then identified 
which transcripts differed between RUN and WL+GR BLOCK to identify potential 
key transcripts and pathways unique to RUN and to WL+GR BLOCK to generate 
new hypotheses.  One such hypothesis is that there is increased triacylglyceride 
turnover in RUN rats, and that BLOCK and WL attenuates this turnover.  This 
hypothesis is based on the up-regulation of Dgat1, Dgat2, and Stat5a combined 
with the lower PRAT total adipocyte number in RUN.  Another hypothesis is that 
there is decreased lipid metabolism in RUN and WL+BR BLOCK rats compared 
to WL rats.  This is based on whole-transcriptome analysis and the top up-
regulated pathways for both [RUN vs. WL] and [WL+GR BLOCK vs. WL] involve 
carbohydrate and lipid metabolism.  We also extended the findings from Chapter 
2 and found that indeed, PRAT from WL animals show increased levels of 
transcripts involved in in cell cycle progression, proliferation, and differentiation 
genes compared to RUN.  Finally, data is presented in this study that can help 
manifest future hypotheses that help further understand how adipose tissue 
responds to a sudden decrease in activity. 
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CHAPTER 4 
 
Discussion 
 
I hope to convey my thought process in developing the hypotheses, 
designing the experiments, and interpreting the results throughout this discussion 
chapter.  I will present my discussion in chronological order and try to be clear 
when a new insight or bit of data was discovered that either altered or shaped the 
way I approached the experiments.    
 
Formulation and testing of hypotheses 
As described in detail in Chapter 1, I formulated my hypothesis based on 
four major questions:   
1) Does the way in which adipose tissue expands depend on the age 
of wheel lock?  
2) How does adipose tissue expand with 7 days of wheel lock?   
3) Is this expansion healthy or unhealthy? 
4) Do glucocorticoids play a role in this adipose tissue expansion?   
My overall hypothesis was that seven days of wheel lock in49-56 day old 
rats and 70-77 day old rats would result in gains in visceral adipose mass seen in 
age-matched sedentary rats concurrent with an increase in adipocyte size and 
inflammatory mRNA expression.  Further, glucocorticoid block would attenuate 
the visceral adipose depot gains seen in wheel lock (WL) in 70-77 day old rats.     
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In order to test these two hypotheses, I needed to implement our WL 
model in a very systematic and organized fashion.  Rats were randomly selected 
from an ongoing rat breeding study in the Booth lab where we are breeding rats 
who are, and who are not, “motivated” to run in a voluntary running wheel.  When 
rats were available, I received anywhere from 2 to 5 male, Wistar rats who were 
“likely to be motivated to run.”  I performed the experiment on the 49-56 day old 
rats first, then, once I had enough rats (statistical power tests indicated that I 
needed at least 6 rats in each group), I moved on to the 70-77 day old rat 
experiment.  From my conversations with Professor Venkataseshu Ganjam, I 
learned that blocking glucocorticoids also prevented enlargement of visceral 
adipose tissue, much like running.  So I decided to compare both running and 
glucocorticoid block at the molecular level to test the hypothesis that their 
molecular mechanisms would be the same.  I assigned rats to the glucocorticoid 
receptor (GR) block experiment at the same time as I was collecting data on the 
70-77 day old rats.  I did this in order to be efficient with rats, running wheels, and 
time.  When possible, I assigned rats from the same family to each experimental 
group.  For example, if I received five rats at one time, I would assign one rat to 
RUN, one to WL, one to SED, one to WL+GR BLOCK and one to WL+VEHICLE.  
There is a great deal of inter-family variability in terms of voluntary running 
distances and body weight.  While there was no way to predict the rats running at 
the time of assigning groups, I maintained a random method of assigning the rats 
(in short, I took a sheet of paper with the rats ID numbers, put them in a can, and 
drew them randomly).  The hope was to distribute the over- and under-achieving 
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rats with regard to voluntary wheel running equally among the groups.  Statistical 
analysis of the data indicates that this worked well (groups of equal voluntary 
physical activity, i.e. groups that were running and groups that were sedentary, 
showed no differences in body weight, body fat, and distance run).   
With this model in place, I tested the overall hypothesis in two 
experiments, each with their own hypothesis.  These were presented in Chapter 
2 and Chapter 3 and will be discussed in the order I performed experiment and 
analyzed the data.  I will first discuss my rationale for interpreting my data in the 
context of childhood obesity, then I will discuss the first experiment I performed 
(presented in Chapter 2) followed by the second experiment I performed 
(presented in Chapter 3).   
 
Rationale for interpreting WL data in the context of childhood obesity 
My approach to interpret data from Chapters 2 and 3 is to put it into the 
context of human childhood growth and childhood obesity.  In this context, and in 
my opinion, these two studies collectively represent one of the most in-depth 
investigations into adipose tissue expansion in a model of childhood obesity.  To 
my knowledge, no one has interpreted a wheel lock or “cessation of physical 
activity” rodent model in the context of childhood growth and catch-up fat, making 
the findings in my dissertation novel and insightful.  Further, no one has 
published adipose tissue phenotype or transcriptome at two separate time points 
in young, growing animals.  There is much more that can be done (see Chapter 
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5), but the studies presented in this dissertation provide new insights into adipose 
tissue expansion in a young, growing animal. 
 The rationale for framing my dissertation work around the childhood 
obesity paradigm is in large part due to the crisis facing the U.S. health system 
led by poor lifestyle choices.  Having worked with adult humans, I realized that, 
anecdotally, it is difficult to change adult behavior.  Scientific studies support my 
observations.  An American Dietetics Association poll reported that 40% of 
overweight people said they did not want to give up their unhealthy lifestyles in 
order to be healthy [219].  Adults often do not adhere to a diet and exercise 
program aimed at improving their health [220, 221], yet people turn to a pill or 
supplement for help losing weight, often with no noticeable benefit [222] due to, 
in my opinion, poor compliance or lack of potency of the supplement or pill.  Also, 
having worked with children and teenagers as public school teacher and coach, I 
realized that, anecdotally, it is easy to get children to be physically active.  
Providing them with the opportunity and environment to stay physically active 
promotes a desire to remain physically active throughout adolescences and 
adulthood, which seems to keep them healthier, more likely to attend classes and 
activities, and more likely to perform better in school.  Again scientific studies 
support my observation.  Tracking studies, while difficult to perform, show that 
physically active children tend to become active adults [223].  There is 
overwhelming evidence that physically active children are sick less and have 
better school attendance [224].  Further, multiple studies provide evidence that 
physically active children have better cognitive function and learning skills [225, 
114 
 
226].  Still, there is clearly more work to be done concerning lifestyle and health 
in children.  Currently, 18% of children between the ages of 6-19 are classified as 
obese [4].  This occurs concurrently with a dramatic decrease in physical activity. 
Troiano et al. [227] measured the physical activity levels of U.S. children by 
accelerometer and found that 42.0% of children between the ages of 6-11 years 
attain sufficient physical activity by the U.S. guidelines (60 minutes of moderate-
to-vigorous activity daily), but in contrast, only 8.0% of children between the ages 
of 12-15 years attain sufficient physical activity.  By the time these children 
graduate from high school, 92.4% of them are not participating in adequate daily 
physical activity.  This sets them on a trajectory for life-long struggles with weight, 
obesity, and metabolic complications, as well as increased risk for depressive-
like disorders [228]. 
Taken together, there is clearly a need to understand the etiology of 
obesity and mechanisms by which children develop obesity and lifestyle choices 
that set them up to be more- or less-likely to develop obesity.  My two studies 
provide unique insight into this paradigm and will be discussed next. 
 
The story from my initial roadmap for Chapter 2, roadblocks, unexpected 
findings, and alternative routes taken to complets my journey to the 
completion of the manuscript in Chapter 2. 
 
In my first study, I tested the hypothesis that 7 days of wheel lock would 1) 
increase the rate of percent body fat growth and adipose depot masses to levels 
seen in age-matched SED rats in both ages of rats; 2) result in a visceral adipose 
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depot expansion via hypertrophy in rats 49-56 days of age and via hyperplasia in 
rats 70-77 days of age, and 3) increase inflammatory mRNAs in adipose tissue 
before other selected categories of mRNAs in rats 49-56 days of age but not 70-
77 days of age.  These hypotheses were based on preliminary data from the 
Booth lab (described in Chapter 1 and Chapter 2), i.e. my literature review on 
adipose expansion and inflammation, and were driven by three of my four major 
questions: 1) Does the way in which adipose tissue expands depend on the age 
of WL?  2)  How does adipose tissue expand with one week of WL?  3) Is this 
expansion healthy or unhealthy?   
At the onset, I posited that WL would evoke significant alterations in pro-
inflammatory genes.  Even though I was primarily looking at inflammation, it is 
clear from the hypotheses that I was also interested in the question of 
hypertrophy versus hyperplasia.  To get a broader snapshot of what was going 
on in adipose tissue with WL, I decided to measure other transcripts that 
represented functional gene categories (pro-inflammatory, hypoxic, adipokine, 
and adipogenic).  I hypothesized that I would see an increase in inflammation 
with WL, but I didn’t want to rule out other interesting things (like proliferation and 
differentiation transcripts).  What ended up being the most interesting finding was 
that WL initiates adipocyte hyperplasia in epididymal adipose tissue (EAT) and 
perirenal adipose tissue (PRAT) of 70-77 day old rats.  This was unexpected, but 
fits nicely into the context of the childhood obesity public health message as I will 
describe in the next few pages.  
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Other studies using a “decrease in physical activity” model in young rats. 
Very few studies have been performed on the effect of voluntary physical 
activity with cessation of physical activity in young animals, specifically in the 
context of visceral adipose tissue expansion and total adipocyte number. Data 
from this dissertation provides additional insight, explanation, and possibly 
resolution into results from previous experiments of this nature.  The studies 
addressing cessation of activity and its effect on adipose tissue are discussed 
next. 
Hatano et al. [229] investigated treadmill exercise training on male, Wistar 
rats age 28-91 days of age.  Hatano found that there were fewer total epididymal 
adipocytes in the treadmill trained rats than in sedentary rats.  My data from 
Chapter 2 provides a possible explanation to this; the reason this is occurring is 
that physical activity or exercise suppresses cell cycle, proliferation, and 
differentiation in adipose tissue. 
Schroeder et al. [230] provided male OLETF rats, an animal model of 
obesity characterized by hyperphagia-induced obesity, and LETO rats, used as a 
control for the OLETF, access to a voluntary running wheel from 22-45 days of 
age, after which time the wheel was locked until sacrifice at 90 days of age.  
Schroeder found no difference in inguinal adipocyte number between LETO rats 
that had access to the running wheels and those that did not, but a higher 
number of adipocytes in OLETF rats that also had access to running wheels.  
The obvious differences between this study and my studies are the time of wheel 
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lock and the duration of wheel lock.  Schroeder locked the wheel at a time that I 
found the adipose tissue to be expanding by hypertrophy and hyperplasia (see 
Chapter 2, Figure 8.)  In addition, the OLETF rat is a model of obesity, while the 
wild-type Wistar is not.  The data from Chapter 2 provides a probable explanation 
as to why Schroeder did not see a difference in adipocyte number; the age of WL 
occurred during an age where we hypothesize there is little to no WL effect on 
adipocyte size or VAT total adipocyte number (Chapter 2, Figure 11).   
Gollisch et al. [231] provided young Sprague-Dawley rats access to 
voluntary running wheels for four weeks.  Gollisch found that voluntary running 
produced smaller subcutaneous and visceral adipocytes than the sedentary 
control rats, but did not alter cell number in either depot.  These results agree 
with previous data from the Booth laboratory [61] as well as data presented in 
Chapter 2 and can be explained by the age of sacrifice.  These rats were also 
sacrificed during the 49-56 day old age, where I found that wheel lock offers little 
to no effect on adipocyte size or VAT total adipocyte number (Chapter 2, Figure 
11).   
Finally, our results resolve previous data discrepancies in the Booth 
laboratory between two WL studies [60, 61] with conflicting results (see 
introduction for details).  The previous two studies were conducted with Fischer 
344 x Brown Norway (FBN) rats, while my studies were conducted with Wistar 
rats.  This rat strain difference aside, I concluded that there was not a 
discrepancy between these two studies, rather both were correct, but the age of 
growth when WL takes place affects whether increase in adipose tissue mass 
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employs increased hypertrophy (49 day old rats) or hyperplasia (70 day old rats).  
We found that adipocyte diameter increased from 49 to 56 days in both RUN and 
SED groups, indicating that at this age rats are still expanding adipocyte mass by 
hypertrophy.  While we can say we did not observe a WL effect, we did observe 
adipose expansion via hypertrophy.  However, in the 70 to 77 day old rats, there 
was a clear cessation of hypertrophic growth, and WL rats exhibited hyperplasia.    
Despite this resolution, a number of potential explanations should be discussed 
in regards to these two rat strains.  Both our current study (Wistar rats) and our 
previous study (FBN rats) [60] used male rats of similar ages and similar duration 
of wheel lock (7 days of WL from 63-70 days of age for FBN rats and 70-77 days 
of age for Wistar rats).  However numerous qualitative differences occurred 
between the two strains.  For the age range during WL, body masses were 
greater in Wistar (351.5 – 417.5 g) vs. FBN (207.2 – 233.8 g) and, compared with 
previous studies, body fat attributes were higher in Wistars in the current study. 
Specifically, % body fat was 8-13% for Wistars vs. 4.1-6.8% for FBN and 
epididymal fat mass was 3-6g for Wistar and 1.2-1.6 g for FBN [60].  These strain 
differences also mirror Levin’s data [120].  In a third strain (Sprague-Dawley), 
Levin et al. found that only 3 wks of voluntary wheel running sufficed to prevent 
increases in adiposity for 10 wks after wheel removal.  Hence, the three strain 
differences may explain divergent findings, which, while may be viewed as a 
limitation to some, may actually reflect the large intra-individual differences in 
susceptibility for fat gain in the human population.  For example, during 
overfeeding of 12 pairs of young, adult, male monozygotic twins, individual 
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changes in body composition and topography of fat deposition varied 
considerably with a range of 4.3 - 13.3 kg [232].  Thus, heterogeneity of fat gain 
characteristics exists in both humans and rats. 
My findings placed in the context of early-life adipocyte number set point. 
As stated above, one major, yet underappreciated, reason that findings 
from this study are highly relevant to the current childhood inactivity and obesity 
public health issue is that puberty is a critical time of adipose tissue expansion [5, 
233], where many believe the number of adipocytes is set in humans for 
adulthood [6]. The first study, to my knowledge, to look at total adipocyte number 
in adolescent (10-18 years of age) was published by Chumlea et al. in 1982 
[234].  Chumlea reported that increases in body fat during adolescents were 
likely due to increased adipocyte number.  Around this time, Roche published in 
1981 the adipocyte-number hypothesis [51], which stated that the number of 
adipocytes is fixed in early life and this number predestines a person to be lean 
or obese depending on the number of adipocytes a person is ‘set’ at.  In 1991, 
Cartwright discussed the switch from adipocyte hyperplasia to hypertrophy at 
~12-14 weeks of age in chickens [50].  Cartwright suggested that adipocyte 
number is more related to body mass development, while adipocyte size is more 
related to body composition [50].  Spalding et al. [6] pioneered work in total 
adipocyte number and turnover that was published in Nature in June of 2008.  
Using 14C incorporation into genomic DNA from nuclear bomb tests in the late 
1950s and early 1960s, Spalding was able to estimate the ‘birth date’ of a cell 
and retrospectively find the age of adipocytes in humans. Spalding concluded 
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that the half-life of the average adipocyte to be ~8.3 years and approximately 
10% of fat cells renew annually in all adult ages and at all levels of body mass 
index.  She further suggests that this number is tightly regulated and dying 
adipocytes are replaced by new adipocytes to maintain an overall consistent 
number of total body adipocytes.   
However, not everyone agrees with Spalding and her adipocyte set-point 
hypothesis.  Sun and Scherer [43] propose the following questions: 1) Given that 
obesity is associated with higher adipocyte turnover due to accelerated adipocyte 
death, might there be situations where adipocyte recruitment (hyperplasia) is 
greater than adipocyte death and we see a net increase in total adipocytes?  2)  
What is the mechanism by which a new adipocyte is recruited to replace a dying 
one?  These are excellent questions that we do not yet have an answer to.  Part 
of Scherer’s skepticism may be due to a study he published in 2007 [54].  
Scherer’s group developed an ob/ob mouse obesity model (ob/ob mice do not 
produce leptin) that overexpressed adiponectin. The result was a very obese 
mouse with a “healthy,” phenotype (normal triglyceride levels, normal visceral 
adipose tissue mass, and normal insulin sensitivity) with an increased number of 
small adipocytes and reduced macrophage infiltration. This occurred concurrently 
with a partitioning of fat away from the viscera such that these ob/ob-adiponectin 
overexpressing mice had increases in subcutaneous adipose depots and a 
visceral depot phenotype that matched wild type animals.  My view is that while 
this is proof that adiponectin is a central player in altering the metabolic 
homeostasis in adipose tissue, and proof that hyperplasia can occur in older 
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rodents, the condition of the mice in this study is a unique genetic condition in 
which adipose tissue in a genetically, obesity-prone animal is induced by another 
genetic modification and thus makes it difficult to translate into a real-life 
situation.  My position as of now is to adopt the working hypothesis that we have 
a relatively stable number of adipocytes that is set after puberty.  I base this 
hypothesis on human [6] and rat [10] literature.  I propose studies to test this 
hypothesis in Chapter 5. 
Whether or not the total adipocyte number is set at early adulthood, it is 
still believed that the more adipocytes a person has, especially visceral 
adipocytes, the more susceptible they become to obesity later in life [7]. If we 
believe that 1) the number of adipocytes is set early in life and remains relatively 
stable throughout the remainder of life and 2)  the more adipocytes you have, the 
more likely you are to become obese it seems to be, at least theoretically, 
advantageous for health to set the total number of visceral adipocytes low.  I 
found that the total adipocyte number in the epididymal and perirenal adipose 
depots remains lower in physically active rats compared to sedentary rats and 
rats that underwent one week of wheel lock (Chapter 2, Figure 8).  This, in and of 
itself, is a novel finding that prompts me to hypothesize that if we keep kids 
physically active through puberty and into early adulthood, they will be less likely 
to become obese later in life.  This paragraph is pure speculation, and I will 
further address my hypothesis in Chapter 5. 
To place my story in its true timeline, it was not until writing this 
dissertation did I begin to integrate my observations in the manuscripts in 
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Chapters 2 and 3.  Therefore following is an overview of my current thinking.  As 
we advance our knowledge about adipose tissue expansion, we will continue to 
evolve in our thinking.  The predominant belief currently is that adipose tissue 
growth after sexual maturity, as seen in adult animals, occurs via hypertrophy [6], 
and only in extreme cases of increased adipose tissue expansion does 
hyperplasia take place [235]. However, location of adipose tissue depots is 
critical as Singh et al. [236] reported that, while abdominal adipose expansion 
occurs via hypertrophy, lower body, subcutaneous expansion occurs via 
hyperplasia.  Clearly we are still learning about adipose tissue expansion, but in 
the context of a young, growing animal, my results from Chapters 2 and 3 
provide novel insight:  in 49-56 day old rats rats, a sudden decrease in physical 
activity shows little to no disturbance in visceral adipocyte phenotype or mRNA 
expression and a “progress as usual” environment.  However, this same 
decrease in physical activity in 70-77 day old rats shows an altered increase in 
visceral total adipocyte number and adipocyte mRNA expression towards 
increased cell cycle, proliferation and differentiation.    
My interpretation of this data is that expansion via hyperplasia in the 49-56 
day old rats was not observed, not because the rats are failing to produce new, 
mature adipocytes, but rather because rats are producing new, mature 
adipocytes during a rapid growth phase. This is where age-matched groups are 
valuable.  The way I identified that the WL group underwent hyperplasia was to 
compare it to the age-matched RUN group.  In the 49-56 day old groups, 
epididymal total adipocyte number was equal between 56d RUN and 56d 7d-WL, 
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thus I concluded that hyperplasia did not take place. However, I also observed an 
increase in epididymal total adipocyte number between 49d RUN and 56d RUN.  
I interpret this to mean that these 49-56 day old rats rats are still undergoing 
hyperplasic adipose expansion even while maintaining daily physical activity.  
Had I not included the age-matched 56 RUN group, it would have been tempting 
to deduce that hyperplasia was occurring in the 49-56 day old rats since 49d 
RUN < 56d 7dWL.  This is clearly not the case. I conclude that 49-56 day old rats 
were going to increase epididymal cell number at a similar rate whether they 
were physically active or wheel locked.  Now, the 70-77 day old rat data tell a 
different story.  There was no difference between 70d RUN and 77d RUN total 
adipocyte number or in 70d SED and 77d SED total adipocyte number in 
epididymal or perirenal depots.  My interpretation of this data is that at this age, 
these rats are no longer undergoing hyperplasic adipose expansion unless there 
is a drastic metabolic disturbance, like wheel lock (sudden decrease in physical 
activity).  What is still unknown is if wheel lock is performed at adulthood, would 
we see an increase in total adipocyte number in these depots.  This question is 
addressed in Chapter 5. 
 
“Healthy” obesity, characterized by smaller adipocytes and absence of an 
inflammatory component, is not the problem.   
I want to be clear that obesity in and of itself is not necessarily the 
problem; rather it is the type of adipose tissue expansion that occurs during 
obesity (hypertrophy versus hyperplasia).  Some forms of obesity actually have a 
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‘healthy’ phenotype [235].  Healthy obesity has been characterized by the 
absence of any metabolic disorder in an obese individual (BMI > 30 kg/m2). In 
addition, adipose tissue of healthy, obese people is characterized by small 
adipocytes [52] and minimal fat in the viscera [237, 238].  So, in this context, my 
study provides valuable insight.  I found a way to lower what I define as the set-
point of total adipocytes (stay physically active).  I also found that if you decrease 
activity at sexual maturity, you see an increase in visceral total adipocyte 
number.  The health effects of this are unknown, but based on current literature 
[23, 26-34, 70], an increase in visceral total adipocyte number is not a favorable 
phenotype for long-term risk for obesity based on adipocyte hypertrophy and the 
fact that more adipocytes is associated with higher risk for developing obesity 
later in life [7].  In my studies, rats that maintained physical activity had ‘healthier’ 
visceral adipocyte phenotypes in terms of body fat %, visceral adipocyte size, 
and visceral total adipocyte number.   
I was obviously surprised that I did not see an increase in any 
inflammatory markers, given that there are numerous studies that point to 
increased adiposity is accompanied by an increase in inflammation [19, 239-
241]. It is clear that physical inactivity leads to accumulation of visceral fat and 
eventually the activation of inflammatory pathways, but in our model, we failed to 
see this.  Studies point to adipose tissue remodeling and extracellular matrix 
components such as collagen as important variables in adipocyte differentiation 
and contributors of adipose tissue inflammation during adipose tissue expansion 
[242-246], but many of these studies were performed in culture, in chronically 
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overweight or obese subjects, or in animal models of high-fat diet induced 
obesity.  Other studies point to hypoxia as a trigger for inflammation in adipose 
tissue expansion and remodeling [104-106].  HIF-1 functions as a master 
regulator of cellular and systemic homeostatic repose to hypoxia by activation 
transcript of many genes, including those involved in energy metabolism, 
angiogenesis, apoptosis, and other genes whose protein products increase 
oxygen delivery or facilitate metabolic adaptation to hypoxia (from 
genecards.org).  I measured mRNA expression of HIF-1, an upstream indicator 
for adipose tissue dysfunction [106].  HIF-1 mRNA expression in WL showed no 
difference compared to RUN or SED animals, suggesting that this pathway is not 
present in our model.  One week of WL may be too brief to initiate the 
inflammatory pathway. Perhaps if we allowed the rats to undergo WL for weeks-
to-months, we would see an increase in visceral adipose inflammatory markers 
compared to physically active rats.  This point is discussed in Chapter 5.  The 
important finding from the mRNA data was that a proliferation gene was up-
regulated in EAT and PRAT of 70-77 day old rats without any changes in 
inflammatory mRNAs.   
 
 
Chapter 3: Glucocorticoid block attenuates fat gains by a different 
mechanism than physical activity. 
While the thought of looking at cell cycle, proliferation, and differentiation 
transcripts was not specifically stated in my overall hypothesis, the findings from 
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Chapter 2 made it clear to me that the “visceral expansion via hyperplasia” story 
needed to be followed up.  So, the primary purpose of Chapter 3 was to examine 
the role of glucocorticoids on the adipose gains during decreased activity, but a 
secondary purpose was added to test the hypothesis presented at the end of 
Chapter 2 that visceral adipose tissue, specifically EAT and PRAT, is expanding 
by hyperplasia in this rat model due to an increase in cell cycle, proliferation, and 
differentiation induced by WL.   
In this study, I tested the hypothesis that compared to WL rats, rats that 
had access to voluntary running wheels and rats that underwent WL plus a 
glucocorticoid receptor block would show similar changes as WL in PRAT 
transcript expression involved in cell cycle, proliferation, and differentiation.  The 
challenge, and dare I say “goal,” of the study in Chapter 3 was to determine 
whether I could administer a drug at the same time as WL that had the same 
suppressive effects on adipose tissue gain as did running.  This concept goes 
against my philosophy as an exercise physiologist, and against the philosophy of 
the Booth Laboratory, in that our goal for humans is that they incorporate 
physical activity into their lifestyle and avoid taking a drug, which, at best, could 
only partly mimic physical activity.  But, in the instances of forced physical 
inactivity, like injury, the idea of taking a drug temporarily to reduce fat gains is 
appealing, practical, and ethical.  In addition, this concept is scientifically justified: 
if we could show that blocking glucocorticoid action had the same effects in a 
visceral adipose depot as maintaining physical activity (wheel running), then we 
could 1) conclude that running interacts with the glucocorticoid system as a 
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means to attenuate fat accumulation and 2) suggest that RU486 administration 
reproduces the PRAT phenotype seen with physically active and is an 
appropriate adipose-maintenance drug in times of decreased physical activity.   
I was not the first person to think about reducing GC action as a ‘fat loss’ 
solution.  Reducing active glucocorticoids (cortisol in humans and corticosterone 
in rodents) is an effective way to combat obesity and metabolic syndrome [247] 
and to treat individuals with excess glucocorticoid levels like Cushing’s syndrome 
[132].  In addition, supplement companies are capitalizing on the concept that 
reduced glucocorticoid (GC) action can help fat loss.  Supplement companies 
have taken advantage of this concept and produced products such as 
CortiSlim™ that putatively reduce cortisol production. Taken together, blocking 
GC action in a situation where we know we will see an increase in adiposity 
seemed like a potential part of an exercise mimetic.   
Of course, this was not what I found.  Physical activity may influence 
glucocorticoid action in the suppression of adipose gains, but physical activity 
mechanistically works through a different pathway than glucocorticoids. I also 
found that RU486 is not an appropriate “physical activity mimetic” because it not 
only suppressed adipose tissue gains with decreased physical activity; it 
suppressed lean body mass gains too, which is not a desired health outcome, 
especially in a growing animal.  This is an important finding, especially in the 
context of our over-supplemented and over-medicated population:  while RU486 
attenuated gains in adipose tissue, it also attenuated gains in lean tissue mass in 
a pre-adult animal model.  While the physiology behind these effects were 
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beyond the realm of the current study, it is worth mentioning, contrary to my 
findings, excessive GCs leads to decreased protein synthesis and increased 
proteolysis [147] and in the presence of excessive GCs, RU486 prevents muscle 
atrophy [148].  I did not see elevated corticosterone levels in my rats and all rats 
were gaining lean body mass, so the lean body mass attenuation I observed was 
an unexpected finding.      
Rationale for choosing a glucocorticoid blocker 
The rationale behind choosing a glucocorticoid blocker as the ‘fat 
attenuation’ drug in Chapter 3 was this: 1) a literature search on GCs and their 
effect on adipose tissue (see introduction for details), and  2) I had been studying 
the enzyme 11-beta hydroxysteroid dehydrogenase type 1 (11HSD-1) with 
Professor Venkataseshu Ganjam prior to formulating this experiment.  I felt it is 
worth discussing this enzyme here because of its powerful role in GC action, and 
because I spent about one year of working on this enzyme in another 
experiment.   
My data on the effects of exercise training on 11HSD -1 in pigs is found 
in Appendix C.  11HSD -1 is a bidirectional enzyme that can activate and 
inactivate GCs, but in most tissues, the reductase activity predominates, thus 
generating active cortisol from inactive cortisone (active corticosterone form 
inactive 11-dehydrocortisone in rodents) [126]. 11HSD -1 is abundantly 
expressed in adipose tissue and is suggested to be a major etiological factor in 
the development of visceral obesity and the metabolic syndrome [126, 152-155].  
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As of late, 11HSD-1 has been targeted as a key enzyme in the local activation 
of GCs in adipose tissue and is currently the focus of some pharmaceutical 
companies as a therapy to lower visceral adipose tissue mass [149].   
The link between glucocorticoids, 11HSD -1, and physical activity is that 
voluntary physical activity in a young, growing animal appears to up-regulate 
11HSD-1 and be protective against metabolic alterations and obesity [248, 249].  
Coutinho et al. [250] found that hamsters that were exercise training had 2.7-fold 
higher 11HSD-1 enzyme activity in visceral adipose tissue compared to 
sedentary hamsters concurrent with less visceral adipose tissue mass.  Campbell 
et al. [73] reported that exercise training increased 11HSD-1 protein in both 
subcutaneous and perirenal adipose tissue in hamsters and concluded that GCs 
were a significant contributor in the adipose tissue phenotype change and 
decreased adipose tissue mass that occurs during exercise training.   Recently, 
Rajia et al. [249] reported that in a model of rodent pup-obesity induced by 
maternal obesity, rats that had access to voluntary running wheels post weaning 
with ad libitum access to a chow diet reduced hypothalamic 11HSD -1 mRNA 
expression and reversed the deleterious metabolic effects of maternal obesity.  
Now, I re-interpret the literature that the metabolic effects may be due to physical 
activity, rather than 11HSD-1.  However, I interpret that when taken together, it 
seems that physical activity increases 11HSD-1 expression in adipose tissue 
and leads to a favorable phenotype. One obvious question that arises is, what 
happens during a sudden decrease in inactivity?  Does this heightened sensitivity 
to GCs that occurs with physical activity and exercise training (discussed in the 
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introduction) along with increased expression of 11HSD-1 causing deleterious 
effects?  It was along this line of thinking that I chose to block the glucocorticoid 
receptor during WL.   
 
Other studies incorporating glucocorticoid block in young rats. 
There are few studies that investigate glucocorticoid block in the context of 
young animals and adiposity, and no study, to my knowledge, that looks at 
glucocorticoids in the context of decreased physical activity.  Langley and York 
[88] found that 15 days of RU486 administration in young 5-week old Zucker rats 
stopped fat deposition in the Zucker rats and increased protein deposition to 
levels seen in lean-vehicle rats.  Laue et al. [251] reported that daily 
administration of RU486 for 2 weeks decreased food intake and body weight gain 
in obese, but not lean, 5-week old female Zucker rats.  In contrast, Havel et al. 
[252] reported that daily administration of RU486 did not affect food intake, but 
did lower body weight in young, 5-week old male and female Zucker rats.  There 
are a few studies investigating RU486 in Wistar rats, but only one study 
measured adipose depot mass.  Stelmanska [253] abolished progesterone-
induced gains on body mass, inguinal fat mass, and expression of genes 
involved with lipogenesis in inguinal adipose tissue.  Given that many of these 
studies were done in a rat model of obesity and all of the above studies were 
void of a physical activity component, my study presented in Chapter 3 provides 
new and novel data:  1)  I present data on the effect of one week of RU486 
treatment in male, Wistar rats in four adipose depots, 2) I present data on RU486 
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as means of attenuating fat gains seen with a sudden decrease in physical 
activity, 3) I present an comprehensive transcriptome profile of RU486 treated 
rats for generation of future hypotheses. 
As was mentioned in Chapter 3, there was no difference in 11HSD-1 
transcript expression between RUN and WL, but WL+GR BLOCK up-regulated 
11HSD-1 mRNA compared to both RUN and WL.  Perhaps, in and of itself, our 
wheel lock model does not provide a robust enough stimulus to affect 11HSD-1 
expression.  This finding may direct future research away from GCs and 
11HSD-1 in this model.    
 
Conclusion 
In summary, I formulated my hypotheses and dissertation around four 
questions, which were addressed and answered in the two studies:   
1) Does the way in which adipose tissue expands depend on the age 
of WL?   
Yes.  WL in 49-56 day old rats had no effect of wheel lock on omental, 
epididymal, and perirenal adipose tissue mass, mean adipocyte diameter, and 
total adipocyte number, while wheel lock on 70-77 day old rats resulted in 
epididymal and perirenal expansion via hyperplasia. 
2) How does adipose tissue expand with 7 days of wheel lock?   
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In 49-56 day old rats, epididymal adipose tissue likely expands by 
hypertrophy, which occurred in the 49-56 day old RUN and SED rats.  
Hyperplasia was not detectable within EAT in 49-56 day old WL rats.  In contrast, 
in 70-77 day old rats, EAT and PRAT expands by hyperplasia.  
3) Is adipose tissue expansion during 7 days of wheel lock healthy or 
unhealthy?  I suggest that this expansion is healthy in terms of a lack of 
inflammatory mRNA expression.  An initial screen of three inflammatory mRNAs 
showed that there was no inflammatory response with wheel lock.  A brief survey 
of inflammatory transcripts from the RNA-Seq data similarly showed no increase 
in inflammation during 7 days of wheel lock.   
4)  Do glucocorticoids play a role in adipose tissue expansion that 
occurs with 7 days of wheel lock?  Blocking the glucocorticoid receptor 
attenuated total body fat gains as well as visceral depot mass gains, so we 
cannot rule out the role of glucocorticoids in this phenomenon.  However, 
glucocorticoid block did not attenuate fat gains through the same pathway or 
mRNA transcript expression as voluntary wheel running did. 
My overall hypothesis was that seven days of wheel lock in rats that are 
49-56 days old and rats that are 70-77 days old would result in gains in visceral 
adipose mass seen in age-matched sedentary rats concurrent with an increase in 
adipocyte size and inflammatory mRNA expression.  This hypothesis was not 
confirmed.  Visceral adipose levels in wheel locked rats did not reach those of 
sedentary rats in either age group.  Additionally, 49-56 day old rats showed 
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different adipose expansion than 70-77 day old rats when compared to age-
matched sedentary and physically active rats.  Finally, there was no inflammatory 
mRNA expression in either age group.  I further hypothesized that glucocorticoid 
block would attenuate the visceral adipose depot gains seen in WL in 70-77 day 
old rats.   This hypothesis was confirmed in that we saw attenuated visceral 
adipose depot gains with the glucocorticoid block, but the pathway by which the 
glucocorticoid block attenuated gains differed from voluntary running.   
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CHAPTER 5 
 
Future Direction 
 
In a recent review from 2013, Efrat and Tepper [254] stated that,  
“There is strong evidence that childhood overweight and obesity 
are risk factors for severe obesity over the whole life course.  In 
fact, longitudinal studies have found that most overweight/obese 
children would become overweight and obese adults.  There is a 
lack of coupling in the scientific literature between adipose tissue 
development and biology to obesity prevention and treatment 
strategies.  This is of utmost importance, especially regarding 
childhood and adolescence, as the major scientific paradigm in 
studies of adiposity is that the major number of adipocytes is set 
for life at this early age.” 
Unfortunately, the work that has been done thus far is clearly not 
adequate, and we have not yet seen a decrease in the absolute number of obese 
and overweight children.  It is my opinion that more research needs to be done to 
understand the interaction between physical activity and adipose tissue 
development in children and adolescents. In that regard, I will suggest a number 
of studies that can be performed using the WL model to address as-of-yet 
unknown answers to questions.  My ideas are presented next.  Each subsection 
represents a study that could be performed. 
 
1. RNA-Sequencing analysis between RUN and WL rats 
My committee agreed upon my dissertation telling a story.  One part of my 
RNA-Seq data fit into the story and was told in Chapter 3.  The study presented 
in Chapter 3 focused on 173 transcripts pertaining to cell cycle, proliferation, and 
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differentiation, but there was much more data that I have access to from this 
RNA-Seq analysis.  In fact, there are 16,610 transcripts that are shared by both 
RUN and WL rats (see Chapter 3).  Using a filtering process described in 
Chapter 3, I found 118 differentially expressed transcripts (DETs), 74 of which 
were up-regulated in RUN rats compared to WL rats, and 44 of which were 
down-regulated in RUN rats compared to WL rats.  In addition, there were 14 
transcripts that met the filtering criteria that were exclusively expressed in RUN 
rats but not in WL rats and 21 transcripts that were exclusively expressed in WL 
rats but not in RUN rats.  The top 10 transcripts for each of these categories are 
found in Chapter 3, Tables 6 and 7.  A complete list of these transcripts is found 
in Appendix A. 
Much of my analysis of RNA-Seq data that did not fit into my dissertation 
has already been completed.  The list of all transcripts that met the filtering 
criteria outlined in Chapter 3 is listed in Appendix A.  In addition, the top 
pathways identified by Ingenuity Pathway Analysis (IPA) are also listed in 
Appendix A.  Unlike the primary purpose of the analysis in Chapter 3 (focus on 
cell cycle, proliferation, and differentiation transcripts), the primary purpose of this 
comprehensive analysis (looking at all transcritps) is to test the hypothesis that 
transcripts related to adipogenesis would be up-regulated in the WL rats.  
Additionally, RNA-Seq efforts were also performed in order to observe other non-
adipogenic pathway transcriptomic differences within perirenal adipose tissue 
between RUN and WL rats in order to generate new hypotheses for future 
experiments using this model. 
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In addition, 5781 unknown transcripts were present in the RNA-Seq 
analysis, meaning that a transcript was expressed in these rats, but when this 
transcript was compared to our transcript library, there was no match.  Of these 
5781 transcripts, 1353 had average RPKM values > 10 (the highest RPKM 
average was 1182.3994) and 2061 had average RP KM values between 1.0 and 
9.99.  This indicates that there are many, medium- and high-expressed 
transcripts that, as of yet, cannot be identified with current data bases. It is quite 
likely that one or two of these as-of-yet-unidentified transcripts could be integral 
in elucidating mechanisms by which WL accumulates visceral fat.   It will 
eventually be possible to identify some, if not all, of these transcripts with in-
depth research by the Booth lab and many others.   
 
2.  Investigate the adipocyte set-point hypothesis with WL 
 As was discussed in Chapter 4, while it is accepted that puberty is a 
critical time of adipose tissue expansion [5, 233, 234], there is not universal 
consensus that the number of adipocytes is set for life at puberty [6, 43].  While I 
have shown that WL induces hyperplasic adipose expansion in 70-77 day old 
rats, we do not know the effects of WL in young adult rats (older than 77 days of 
age).  Does the adipocyte set-point hypothesis hold?  Do rats maintain a steady 
number of adipocytes when WL is performed after the adipocyte number is ‘set’?  
Human studies suggest that adipocyte expansion in adults occurs via 
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hypertrophy [6] and only in extreme cases of obesity does hyperplasia occur 
[235].   
My working hypothesis is that we have a relatively stable number of 
adipocytes that is set after puberty, and locking wheels in adulthood will lead to 
hypertrophic adipose expansion.  This hypothesis can be tested by allowing rats 
access to a voluntary running wheel through 91 days of age.  Rat literature 
suggests that adipocyte number plateaus around 12 weeks of age [10].  A subset 
of rats would undergo one week of WL at 91 days of age.  A design similar to the 
one described in Chapter 2 would be employed to investigate body mass, lean 
mass, fat mass, % body fat, OAT, EAT, and PRAT depot mass, adipocyte 
diameter, and depot adipocyte total adipocyte number.    
Should we find that, in fact, WL does not induce visceral adipose 
expansion via hyperplasia in adult rats, it would support Spalding’s findings [6] 
that there is a relatively tight regulation of adipocyte number after puberty.  If we 
find that WL during adulthood induces hyperplasic visceral adipose expansion, a 
case can be made that adipose tissue is quite dynamic and has the ability to 
expand via hyperplasia into adulthood.  Either way, the finding would fill a void in 
adipose literature and would help to shape communication to encourage physical 
activity in children in the context of life-long health. 
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3.  Investigate whether daily physical activity through puberty protects 
from obesity later in life 
If a fetus is exposed to prenatal growth restraint, then provided with 
sufficient calories as a newborn, these babies develop spontaneous catch-up 
growth, but still have a marked reduction of SAT in early infancy [255].  This 
reduction in SAT during development has been suggested to confer long-term 
risk for metabolic diseases such as insulin resistance when calorie supplies 
become available [256, 257].   When I learned this, I had the question, “Does 
maintaining a low set-point of whole-body total adipocyte number through and 
after puberty provide a protective effect or is it a risk factor for future metabolic 
disease?”  
This is a follow-up to the previously suggested study #2.  If we find that 
adipocyte number is set for life after puberty, are rats and children “protected” 
from obesity or an unhealthy adipose tissue phenotype throughout life, or are 
they more at risk?  As much as I would like to believe that daily physical activity 
through childhood and early adulthood is protective, the data, specifically that 
adulthood adipose tissue expansion via hypertrophy predominates [6], leads me 
to a different hypothesis.  I hypothesize that a sedentary (WL) condition in 
adulthood after previously undergoing daily physical activity, will lead to an 
hypertrophic visceral adipose tissue expansion accompanied with a “unhealthy,” 
pro-inflammatory adipose tissue phenotype. 
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The rationale for this hypothesis is that if:  1) a greater number of 
adipocytes at puberty increases risk for developing obesity later in life [7], 2) 
adipocyte number is set at puberty [6, 10] and to be determined the suggested 
study #2), and 3) adipose tissue expansion can only occur through hypertrophy 
later in life (to be determined from the suggested study #2) then, adult-onset 
adipose tissue expansion is likely to carry an unhealthy phenotype including 
increased expression of pro-inflammatory mRNAs. 
4. Investigate the effect of cyclic physical activity (activity-inactivity-
activity-inactivity…) on adipose tissue.   
This study is also a follow up to proposed study #2.  If the effect of WL in 
young rats induces hyperplasia, what does the effect of repeated bouts of WL 
do?  For example, if we WL a rat at 70-77 days of age (where I found both 
hyperplasic visceral adipose growth), then allow the rat access to a running 
wheel at 77-91days of age, then WL again at 91-97 days of age (results of 
proposed study #2 will provide data on visceral adipose tissue response to WL at 
this age), will we see an exaggerated hyperplasic response (i.e. would WL done 
twice on rats exhibit more visceral total adipocyte number than WL done once?).  
This situation mimics life nicely; children are active during the summer, then are 
forced to sit quietly in school, so the public health message from this study has 
potential to be powerful.  
Since no study has been done like this before, any hypothesis is purely 
speculation.  However, there is a little information on exercise training in rats at 
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70-77 days of age.  Jenkins et al. recently published a study where they began 
exercise training OLETF rats at 19 weeks of age through 30-32 weeks of age 
[110].  They found that when compared to rats that were not exercise trained, 
rats that were exercise trained had lower omental, retroperitoneal, and 
epididymal fat depot masses but similar adipocyte diameters.  This rat strain and 
age differs from the Wistars used in my proposed study #4, but I am comfortable 
hypothesizing that running between the ages of 77-91 days would reduce 
visceral adipose mass.  Sticking with my working hypothesis that rats have a 
relatively stable number of adipocytes that is set after puberty, increased activity 
(i.e. treadmill running like in Jenkins’ study or WL in my studies) after puberty 
decreases visceral adipose mass, and locking wheels in adulthood will lead to 
hypertrophic adipose expansion, I hypothesize that RUN/WL/RUN/WL rats would 
exhibit greater visceral adipose depot masses and more visceral total adipocyte 
number than rats who had access to a voluntary running wheel the entire 97 
days, but less visceral mass, but bigger adipocytes than rats who underwent only 
one bout of WL at either 70 days (Chapter 2) or 91 days (proposed experiment 
#2). 
 
5.  Other potentially interesting investigations 
5a. Investigate WL effects on female rats.  All of the experiments in my 
dissertation were performed on male, Wistar rats.  These experiments could be 
repeated with female rats to determine if there is a similar effect or if there a sex-
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specific attenuation or augmentation of visceral adipose expansion induced by 
WL exists, as female Wistar rats voluntarily run almost twice the distances of 
male rats.   
5b. Acute molecular changes w/ WL.  I employed one week of WL before looking 
at transcript profiles, but there may be interesting changes occurring within the 
first hours or 1-2 days of WL.  Food intake data from Chapter 2 show a rapid 
decrease in food intake over 3 days.  Feed efficiency also showed highly variable 
levels the first 3 days of WL. The same experimental design could be applied as 
described in Chapter 2, but rats were sacrificed earlier.  Molecular markers could 
be investigated to help understand acute mechanisms of decreased activity in 
adipose tissue. 
5c. Perform RNA-Seq on liver.  Given the important role of the liver in fatty acid 
metabolism, turnover, and partitioning [258, 259], it would be interesting to 
investigate the transcriptome of livers of RUN and WL rats.  Perhaps some 
insight could be gained into fatty acid metabolism and redistribution during WL in 
our model.  Some work has already been done in regards to WL and liver.  Laye 
et al. [95] found that one week of WL after 6 weeks of voluntary wheel running in  
Fischer 344 x Brown Norway F1 hybrid rats increased hepatic fatty acid oxidation 
above RUN and sedentary levels.  Rector et al. [260] found that one week of WL 
after 16 weeks of voluntary wheel running in OLETF rats activated processes 
that initiate hepatic steatosis with no changes in body weight and no changes in 
omental and retroperitoneal adipose depots.  Despite this insight, little is known 
about hepatic response to WL in our model of WL. 
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5d. Markers of hyperplasia in vivo.  It would be interesting use in vivo measures 
of hyperplasia and hypertrophy.  For example, we could use 2H2O labeling and 
mass spectrometry analysis [261] and BrdU injections [262] in conjunction with 
WL.  Using these methods could add to our understanding of adipose tissue 
expansion in the WL model and provide another line of evidence  supporting my 
hyperplasia hypothesis. 
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TABLE A1.  73 Up-regulated transcripts from RNA-Seq analysis.   
NAME OF TRANSCRIPT SYMBOL 
RUN RPKM 
AVERAGE 
WL RPKM 
AVERAGE RUN/WL P-VALUE 
regulatory factor X, 4 (influences HLA class II expression) (Rfx4) 2.436 0.761 3.202 0.0004 
gastric inhibitory polypeptide receptor (Gipr) 2.094 0.768 2.725 0.0017 
Kv channel interacting protein 1 (Kcnip1) 15.105 6.149 2.456 0.0005 
calmodulin-like 3 (Calml3) 8.972 3.803 2.359 0.0018 
SIX homeobox 4 (Six4) 2.459 1.070 2.290 0.0002 
alcohol dehydrogenase, iron containing, 1 (Adhfe1) 49.273 21.536 2.288 0.0003 
uncoupling protein 3 (Ucp3) 25.046 11.802 2.122 0.0018 
cytochrome P450, family 4, subfamily F, polypeptide 22 (Cyp4f22) 16.684 8.072 2.067 0.0028 
carboxylesterase 5 (Ces2) 2.369 1.186 1.997 0.0005 
growth hormone regulated TBC protein 1 (Grpt1) 1.861 0.932 1.996 0.0036 
reticulon 4 (Rtn4) 270.074 138.891 1.945 0.0016 
carrier family 25, member 35 (Slc25a35) 43.719 22.546 1.939 0.0018 
calcium/calmodulin-dependent protein kinase II beta (Camk2b) 7.131 3.712 1.921 0.0041 
purinergic receptor P2X, ligand-gated ion channel, 5 (P2rx5) 24.384 12.746 1.913 0.0007 
ciliary neurotrophic factor (Cntf) 5.948 3.157 1.884 0.0002 
1-acylglycerol-3-phosphate O-acyltransferase 2  (Agpat2) 394.366 219.378 1.798 0.0024 
cysteine conjugate-beta lyase 2 (Ccbl2) 21.503 11.995 1.793 0.0004 
carbonic anhydrase 3 (Ca3) 1326.502 741.588 1.789 0.0008 
androgen-induced 1  (Aig1) 72.044 40.701 1.770 0.0007 
diazepam binding inhibitor (Dbi) 5.247 2.969 1.767 0.0022 
branched chain amino-acid transaminase 2, mitochondrial (Bcat2) 97.259 55.714 1.746 0.0003 
protein phosphatase 1, regulatory (inhibitor) subunit 1A (Ppp1r1a) 61.494 35.251 1.744 0.0001 
fatty acid binding protein 4, adipocyte (Fabp4) 18261.061 10506.097 1.738 0.0006 
acyl-CoA oxidase 1, palmitoyl (Acox1) 163.670 94.242 1.737 0.0004 
angiotensin I converting enzyme (peptidyl-dipeptidase A) 2  (Ace2) 1.668 0.967 1.725 0.0049 
phosphoserine phosphatase (Psph) 28.171 16.389 1.719 0.0021 
phospholipase A2, group XVI (Pla2g16) 1129.234 658.953 1.714 0.0006 
CD300 molecule-like family member g (Cd300lg) 5.119 2.995 1.709 0.0016 
3-oxoacid CoA transferase 1 (Oxct1) 183.745 108.171 1.699 0.0002 
cysteine dioxygenase, type I (Cdo1) 1446.001 856.056 1.689 0.0000 
up-regulated during skeletal muscle growth 5 (Usmg5) 5.843 3.470 1.684 0.0010 
adipogenin  (Adig) 741.757 440.576 1.684 0.0050 
s family with sequence similarity 73, member B (Fam73b) 2.460 1.461 1.683 0.0033 
glutathione transferase zeta 1 (Gstz1) 61.024 36.291 1.682 0.0031 
succinate receptor 1 (Sucnr1) 48.798 29.033 1.681 0.0049 
N-acetyltransferase 8-like (Nat8l) 54.036 32.259 1.675 0.0014 
1-acylglycerol-3-phosphate O-acyltransferase 9  (Agpat9) 58.907 35.180 1.674 0.0000 
cytochrome b5 reductase 1 (Cyb5r1) 320.072 192.195 1.665 0.0032 
adrenoceptor beta 3  (Adrb3) 93.412 56.269 1.660 0.0048 
MACRO domain containing 1 (Macrod1) 29.901 18.118 1.650 0.0008 
pleckstrin homology domain containing, family B (evectins) 
member 1 (Plekhb1) 8.915 5.425 1.643 0.0008 
asparagine synthetase (Asns) 64.760 39.666 1.633 0.0033 
enoyl-CoA delta isomerase 1 (Eci1) 86.291 52.892 1.631 0.0006 
UFM1-specific peptidase 1 (Ufsp1) 5.916 3.635 1.627 0.0036 
acyl-CoA thioesterase 13  (Acot13) 17.082 10.513 1.625 0.0012 
BRCA1-associated protein (Brap2) 1.856 1.155 1.608 0.0001 
glutathione S-transferase alpha 5 (Gsat5) 2.223 1.384 1.606 0.0003 
cell death-inducing DFFA-like effector c (Cidec) 979.814 615.201 1.593 0.0002 
carboxymethylenebutenolidase (Cmbl) 97.351 61.228 1.590 0.0009 
MPV17 mitochondrial membrane protein-like (Mpv17l) 3.451 2.176 1.586 0.0005 
3-hydroxy-3-methylglutaryl-CoA synthase 1 (Hmgcs1) 62.952 39.811 1.581 0.0007 
ubiquinol-cytochrome c reductase, complex III subunit XI (Uqcr11) 8.074 5.117 1.578 0.0030 
cytochrome c oxidase, subunit VIc-like (Cox6c) 6.453 4.100 1.574 0.0000 
chemokine (C-C motif) ligand 27  (Ccl27) 1.753 1.116 1.571 0.0007 
pyruvate dehyrogenase phosphatase catalytic subunit 2 (Pdp2) 10.458 6.667 1.569 0.0014 
protein-O-mannosyltransferase 2 (Pomt2) 24.033 15.359 1.565 0.0013 
neuregulin 4 (Nrg4) 23.397 14.978 1.562 0.0005 
chromosome 15 open reading frame 61 (C15orf61) 14.544 9.382 1.550 0.0032 
heat shock 10kDa protein 1 (chaperonin 10) (Hspe1) 223.989 144.888 1.546 0.0023 
RAN guanine nucleotide release factor (Rangfr) 24.043 15.553 1.546 0.0009 
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coiled-coil-helix-coiled-coil-helix domain containing 3 (Chchd3) 6.915 4.483 1.543 0.0003 
ATP synthase, H+ transporting, mitochondrial Fo complex, 
subunit C3 (Atp5g3) 91.714 59.593 1.539 0.0016 
CD36 molecule (thrombospondin receptor) (Cd36) 634.178 412.685 1.537 0.0001 
coiled-coil-helix-coiled-coil-helix domain containing 2 (Chchd2) 657.043 428.463 1.533 0.0008 
potassium voltage-gated channel, subfamily H, member 2  (Kcnh2) 18.340 11.967 1.533 0.0016 
cysteine sulfinic acid decarboxylase (Csad) 57.754 37.770 1.529 0.0012 
thyroid hormone receptor alpha (Thra) 1.298 0.851 1.526 0.0003 
DnaJ (Hsp40) homolog, subfamily C, member 15 (Dnajc15) 66.949 44.377 1.509 0.0004 
phytanoyl-CoA 2-hydroxylase (Phyh) 409.641 271.633 1.508 0.0003 
quinoid dihydropteridine reductase (Qdpr) 152.631 101.218 1.508 0.0012 
S100 calcium binding protein A1 (S100a1) 17.345 11.527 1.505 0.0045 
protein tyrosine phosphatase, receptor type, R (Ptprr) 2.774 1.844 1.504 0.0029 
fat storage-inducing transmembrane protein 2 (Fitm2) 57.298 38.184 1.501 0.0021 
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TABLE A2.  44 Down-regulated transcripts from RNA-Seq analysis  
NAME OF TRANSCRIPT SYMBOL 
RUN RPKM 
AVERAGE 
WL RPKM 
AVERAGE RUN/WL P-VALUE 
kinesin family member 18B (Kif18b) 0.217 1.519 -6.997 0.0025 
budding uninhibited by benzimidazoles 1 homolog beta (Bub1b) 0.316 2.162 -6.831 0.0036 
ubiquitin-conjugating enzyme E2C (Ube2c) 1.097 7.307 -6.660 0.0035 
cytoskeleton associated protein 2-like (ckap2l) 0.266 1.721 -6.479 0.0016 
protein regulator of cytokinesis 1 (Prc1) 1.583 9.570 -6.044 0.0012 
cyclin-dependent kinase 1 (Cdk1) 1.559 9.152 -5.869 0.0047 
family with sequence similarity 64, member A (Fam64a) 0.445 2.557 -5.741 0.0015 
kinesin family member 2C (Kif2c) 0.226 1.223 -5.408 0.0019 
kinesin family member 20B (Kif20b) 0.251 1.277 -5.078 0.0021 
trophinin associated protein (tastin) (Troap) 0.300 1.496 -4.979 0.0029 
diaphanous homolog 3 (Diaph3) 0.349 1.644 -4.709 0.0007 
polo-like kinase 4 (Plk4) 0.446 1.983 -4.442 0.0044 
centromere protein E, 312kDa (Cenpe) 0.380 1.633 -4.293 0.0014 
non-SMC condensin I complex, subunit G (Ncapg) 0.588 2.110 -3.589 0.0013 
centromere protein M (Cenpm) 0.508 1.682 -3.310 0.0036 
microfibrillar-associated protein 4 (Mfap4) 16.300 53.474 -3.281 0.0018 
piezo-type mechanosensitive ion channel component 2 (Piezo2) 0.392 1.260 -3.211 0.0031 
chromatin licensing and DNA replication factor 1 (Cdt1) 0.604 1.900 -3.146 0.0038 
 inner centromere protein (Incenp) 1.062 3.113 -2.931 0.0011 
thyroid hormone receptor interactor 13 (Trip13) 0.435 1.249 -2.874 0.0015 
forkhead box M1 (Foxm1) 0.804 2.225 -2.766 0.0028 
v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (Erbb3) 1.613 3.977 -2.465 0.0030 
transcription factor 19 (Tcf19) 4.152 9.333 -2.248 0.0048 
thrombospondin 3 (Thbs3) 3.450 7.676 -2.225 0.0026 
vestigial like 3 (Vgll3) 6.646 14.263 -2.146 0.0013 
Rho GTPase activating protein 11A (Arhgap11a) 2.927 6.205 -2.120 0.0009 
chromatin assembly factor 1, subunit A (p150) (Chaf1a) 1.395 2.868 -2.056 0.0003 
neuron navigator 2 (Nav2) 0.618 1.175 -1.902 0.0034 
tensin 3 (Tns3) 3.181 5.873 -1.847 0.0006 
kin of IRRE like (Kirrel) 7.471 13.514 -1.809 0.0003 
asporin (Aspn) 20.547 37.142 -1.808 0.0026 
zinc finger protein 367 (Znf367) 2.260 4.080 -1.805 0.0017 
POU class 2 homeobox 2 (Pou2f2) 0.495 0.865 -1.746 0.0036 
major histocompatibility complex, class I, H (Hla-h) 18.643 32.440 -1.740 0.0015 
structural maintenance of chromosomes 2 (Smc2) 4.259 7.147 -1.678 0.0033 
RCAN family member 3 (Rcan3) 2.857 4.757 -1.665 0.0020 
cathepsin K (Ctsk) 19.441 31.855 -1.639 0.0033 
cyclin-dependent kinase 6 (Cdk6) 3.934 6.325 -1.608 0.0040 
placenta-specific 9 (Plac9) 29.429 47.112 -1.601 0.0026 
drebrin 1 (Dbn1) 5.341 8.502 -1.592 0.0037 
outer dense fiber of sperm tails 2-like (Odf2l) 1.387 2.159 -1.556 0.0011 
UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 9 (B2gnt9) 4.071 6.239 -1.533 0.0029 
ring finger and WD repeat domain 3 (Rfwd3) 2.366 3.573 -1.510 0.0009 
eukaryotic translation initiation factor 2C, 2 (Eif2c2) 2.501 3.769 -1.507 0.0006 
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Table A3.  Top up-regulated IPA pathways for RUN vs. WL 
Carbohydrate Metabolism, Cellular Function and Maintenance, Small 
Molecule Biochemistry (Score: 59) 
Acox1, Adrb3, Agpat2, Agpat9, Aig1, Asns, Bcat2, Ca3, Cd36, 
Chchd2, Cntf, Dbi, Fabp4, Gsta5, Hspe1, Kcnh2, Nrg4, Oxct1, 
Pla2g16, Ppp1r1a, Ptprr, S100a1, Sucnr1, Thra 
 
Developmental Disorder, Hereditary Disorder, Neurological Disease 
(Score: 28) 
Acot13, Ccbl2, Cmbl, Cyb5r1, Cyp4f22, Eci1, Fitm2, Grtp1, Pdp2, 
Pomt2, Qdpr, Rangrf, Usmg5   
 
DNA Replication, Recombination, and Repair, Nucleic Acid 
Metabolism, Small Molecule Biochemistry (Score: 25) 
Ace2, Adig, Atp5g3, Calml3, Chchd3, Cidec, Csad, Dbi, Hmgcs1, 
Mpv17l, Plekhb1, Psph, Six4 
 
Molecular Transport, Amino Acid Metabolism, Lipid Metabolism 
(Score: 21) 
Adhfe1, Cam2b, Cnajc15, Gipr, Kcnip1, Macrod1, Nat8l, P2rx5, 
Phyh, Rtn4, Ucp3 
 
 
 
Table A4.  Top down-regulated IPA pathways for RUN vs. WL 
Cell Cycle, Cellular Assembly and Organization, DNA Replication, 
Recombination, and Repair (Score: 55) 
Bub1b, Cdk1, Cdk6, Cdt1, Cenpe, Chaf1a, Ctsk, Dbn1, Eif2c2, 
Erbb3, Foxm1, Incenp, Kif20b, Kif2c, Ncapg, Odf2l, Plk4, Prc1, 
Smc2, Tns3, Trip13, Ube2c   
 
Cancer, Cellular Development,Infectious Disease (Score: 40) 
Arhgap11a, B3gnt9, Cenpe, Cenpm, Ckap2l, Fam64a, H2-t24, 
Incenp, Kif18b, Kirrel, Pou2f2, Rcan3, Rfwd3, Tcf19, Troap 
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Table A5.  14 transcripts that are expressed in RUN but not WL 
NAME OF TRANSCRIPT SYMBOL 
RPKM 
VALUE 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked (Ddx3x) 18.005 
glycosylation dependent cell adhesion molecule 1  (Glycam1) 9.086 
homeobox A9 (Hoxa9) 6.562 
macrophage receptor with collagenous structure (Marco) 5.820 
uroplakin 1A (Upk1a) 2.741 
5S RNA  (Rna5s3) 2.641 
 casein alpha s2-like A (Csn1s2a) 2.253 
synaptophysin-like 2 (Sypl2) 2.221 
xin actin-binding repeat containing 2 (Xirp2) 2.078 
ankyrin repeat domain 23 (Ankrd23) 1.238 
glucocorticoid induced transcript 1 (Glcci1) 1.168 
leiomodin 3 (Lmod3) 1.258 
popeye domain containing 3 (Popdc3) 1.099 
epithelial cell adhesion molecule (Epcam) 1.054 
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Table A6. 32 transcripts that are expressed in WL but not RUN 
 
NAME OF TRANSCRIPT SYMBOL 
RPKM 
VALUE 
carboxypeptidase B1 (Cpb1) 114.338 
phospholipase A2, group IB  (PLA2G1B) (Pla2g1b) 70.900 
protease, serine, 3 (Prss3) (Prss3) 65.286 
colipase, pancreatic (CLPS) (Clps) 53.700 
prepronociceptin (PNOC) (Pnoc) 41.326 
pancreatic lipase-related protein 1 (Pnliprp1) (Pnliprp1) 34.388 
syncollin (SYCN) (Sync) 30.699 
protease, serine, 2 (trypsin 2) (PRSS2) (Prss2) 12.454 
BARX homeobox 1 (Barx1) (Barx1) 11.817 
C2 calcium-dependent domain containing 4D (C2cd4d) (C2cd4d) 5.089 
serine peptidase inhibitor, Kazal type 1 (SPINK1) (Spink1) 3.689 
norvegicus glycerophosphodiester phosphodiesterase domain 
containing 2 (Gdpd2) (Gdpd2) 2.619 
 D4, zinc and double PHD fingers family 1 (DPF1) (Dpf1) 2.044 
angiotensin II receptor, type 2 (AGTR2) (Agtr2) 1.885 
serine (or cysteine) peptidase inhibitor, clade I, member 2 
(Serpini2) (Serpini2) 1.635 
synaptosomal-associated protein, 25kDa (SNAP25) (Snap25) 1.620 
protein disulfide isomerase family A, member 2 (Pdia2) (Pdia2) 1.614 
 runt-related transcription factor 1; translocated to, 1 (cyclin D-
related) (RUNX1T1) (Runx1t1) 1.388 
geminin coiled-coil domain containing (GMNC) (Gmnc) 1.388 
endoplasmic reticulum protein 27 (Erp27) (Erp27) 1.221 
chemokine (C-C motif) receptor 3 (Ccr3) (Ccr3) 1.209 
retinol binding protein 2, cellular (RBP2 (Rbp2) 1.200 
sodium channel, voltage-gated, type III, alpha subunit (SCN3A) (Scn3a) 1.134 
SLIT and NTRK-like family, member 2 (Slitrk2) (Slitrk2) 1.047 
family with sequence similarity 83, member D (Fam83d) (Fam83d) 1.016 
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APPENDIX B 
 
 
 
Epicardial fat gene expression after aerobic exercise training in pigs with 
coronary atherosclerosis: relationship to visceral and subcutaneous fat 
Published in J Appl Physiol 109: 1904-1912, 2012 
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APPENDIX C 
 
 
 
11HSD-1 enzyme activity assay, immunohistochemistry staining,  
and lipolysis in FHM pigs 
 
 
Unpublished data 
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The overall question for the 11HSD-1 FHM pigs was: Does 11HSD-1 
activity in various adipose tissue depots correlate with lipolysis? 
For my initial experiment using FHM4 pigs, I hypothesized that exercise 
would decrease omental adipose tissue by maintaining smaller adipocytes and 
increasing lipolysis.  I examined three variables:  1) adipose tissue distribution, 2) 
adipocyte size, and 3) lipolysis.  I found that exercise did not reduce omental 
adipose tissue in the exercised pigs (Table C1) and omental adipocytes were not 
smaller (Figure C2), but omental adipose tissue had higher basal lipolysis than 
subcutaneous adipose tissue, and exercise seems to augment this response 
(Figure C3).  Also, we found that exercise may increase 11HSD-1 protein and 
activity in FHM5 pig adipose tissue (epicardial, omental, and subcutaneous 
adipose tissue) (Arce and Ganjam, unpublished data) (Figure C4 & C6).  In 
addition, we found that omental adipose tissue has higher levels of 11HSD-1 
protein and activity than subcutaneous adipose tissue (Arce and Ganjam, 
unpublished data).  Typically, 11HSD-1 activates glucocorticoids, but, as of 
now, we are not certain if 11HSD-1 in exercised adipose tissue activates 
(reduces) or inactivates (oxidizes) glucocorticoids.  The connection between 
11HSD-1 and lipolysis is that cortisol (active form of glucocorticoids) stimulates 
lipolysis. 
In addition to the above experiments (fat distribution, adipocyte size, and 
lipolysis), another thing I would like to do is measure both the reductase and 
188 
 
oxidase activity of 11HSD-1 to determine which direction the enzyme is going in 
our pig adipose samples (subcutaneous, omental, and epicardial adipose tissue).   
Given that 11HSD-1 is predominantly an activator (reductase) of 
glucocorticoids, and since glucocorticoids are known to increase lipolysis, for the 
FHM6 pigs, I hypothesize that exercised pigs will exhibit more 11HSD-1 protein 
and reductase activity in omental adipose tissue, which will promote increased 
omental lipolysis and possibly contribute to adipose tissue redistribution away 
from omental adipose tissue. 
Since there are only three other publications investigating 11HSD-1 and 
exercise, this data would be novel and contribute to the growing body of 
11HSD-1 literature and help us understand how this enzyme affects adipose 
tissue in an exercise model.  In addition, there is no data on epicardial adipose 
tissue in this context; this would be the first time exercise, lipolysis, and 11HSD-
1 would be investigated in epicardial adipose tissue.   
Below are figures from data that has been collected for this project.  These 
figures would be similar to the type of figures that I feel would be necessary to 
include in a manuscript to tell this story.  Additional information I would like to 
collect is indicated in red italics under the figures. 
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Figure C1.  Experimental design 
Two cohorts of pigs were randomly selected to be either exercise trained (EX) on 
a treadmill or remain sedentary (SED) (see Appendix B for exercise protocol).  At 
14 months of age, both groups were put on a high fat diet.  Pigs were sacrificed 
at 20 months of age.  
 
 
 
Table C1.  Pig Characteristics 
  FHM 4 FHM4 EX FHM4 SED  
  n=14 n=8 n=6  
Body Weight (kg) 85.3 ± 2.3 86.1 ± 2.6 84.2 ± 4.3  
%BF (DXA) 34.7 ± 1.2 35.7 ± 1.1 33.4 ± 2.6  
Fat wt (kg) 29.7 ± 1.5 30.8 ± 1.7 28.3 ± 2.9  
OM weight (g) 256.4 ± 28.1 299.8 ± 40.4 198.5 ± 23.7  
%OM of total fat 0.84 ± 0.06 0.95 ± 0.09 0.70 ± 0.05  
Waist Circ. (in) 42.1 ± 0.7 42.2 ± 0.65 42.0 ± 1.4  
WC/BW 0.50 ± 0.01 0.49 ± 0.01 0.50 ± 0.01  
There was a trend for more omental weight  (p = 0.072) and percent of total 
omental fat (0.054) in the exercised pigs. 
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Figure C2.  Adipocyte size from FHM4 pigs.   
 
 
Omental adipocytes are larger than subcutaneous adipocytes.  Exercise may 
mitigate this effect. 
 
 
 
 
Figure C3. Lipolysis from FHM4 pigs. 
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A glycerol assay was used to evaluate lipolysis in these pigs. Omental 
adipocytes show more basal metabolic activity than subcutaneous.   
 
Figure C4. 11HSD-1 enzyme activity in FHM5 pigs (Oxidase activity) 
 
There appeared to be more 11HSD-1 oxidase activity in exercise pigs.  This 
data was confirmed with immunohistochemistry staining for 11HSD by Dr. 
Arturo Arce.  The next two figures are work done by Dr. Arce. 
 
Figure C5.  IHC staining for 11HSD-1 in FHM5 adipose tissue (from Arce) 
 
EX pigs had more 11HSD-1 staining than SED pigs.  The data is quantified 
below. 
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Figure C6. 11HSD-1 protein in FHM4 pigs (from Arce) 
 
EX pigs appeared to have more 11HSD-1 protein than SED pigs.   
Unfortunately, the assay was unable to be performed on any subsequent cohorts 
of pigs, and the project was halted.   
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APPENDIX D 
 
 
 
Investigation on chronic high fat diet versus low fat diet on Wistar rats: 
Adipocyte distribution, adipocyte size and lipolysis 
 
 
Unpublished data 
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The purpose of this experiment was to evaluate the effect of a high fat diet 
on body fat, adipose distribution, and lipolysis.   
At ~5 weeks of age, male Wistar rats were randomly selected to either a 
normal chow diet (LFD) or high fat diet (HFD).  Rats were on this diet for 22 
weeks, and were sacrificed at ~27 weeks of age (191-194 days of age). A group 
of rats was sacrificed at 103-117 days of age to serve as a young, control. 
Plasma was collected at the time of sacrifice for a glycerol assay.  The 
following measurements were performed:  weight, length, DXA % body fat, 
omental (OM) depot mass and adipocyte diameter, epididymal (EPI) depot mass 
and adipocyte diameter, and subcutaneous (SQ) adipocyte diameter.  Fat mass, 
lean mass, % body fat that is OM and % body fat that is EPI were calculated.  
Results are below. 
Table D1. Anthropometric and adipose characteristics of young, HFD, and LFD rats. 
 
A lipolysis assay (glycerol assay) was performed from the plasma (Figure 
D1).  The glycerol assay quantifies free glycerol in plasma and is a marker of 
age at days on weight length fat lean
sacrifice HFD (g) (cm) % BF mass (g) mass (g)
YOUNG 110.1 ± 7.0 * # n/a 456.6 ± 24.7 *  # 25.8 ± 0.7 * # 16.8 ± 1.3 * # 76.9 ± 7.5 * # 397.8 ± 21.7 * #
LFD 191.8 ± 0.9 ^ n/a 724.7 ± 40.7 ^ 29.0 ± 0.5 ^ 28.5 ± 1.0 ^ # 207.0 ± 15.6 ^ # 517.6 ± 28.3 ^
HFD 193.6 ± 1.1 ^ 160.3 ± 1.2 747.2 ± 27.0 ^ 28.4 ± 0.5 ^ 39.5 ± 3.9 ^ * 298.9 ± 36.1 ^ * 448.3 ± 24.1 ^
* vs LFD
# vs HFD
^ vs YOUNG
OM AT % BF EPI AT % BF OM A size EPI A size SQ A size
mass (g) OM mass (g) EPI (mm) (mm) (mm)
YOUNG 1.2 ± 0.1 * # 0.3 ± 0.0 * # 8.6 ± 0.7 *  # 1.9 ± 0.1 * # 64.1 ± 3.0 # 64.1 ± 3.1 # 60.0 ± 3.9 #
LFD 3.4 ± 0.2 ^ # 0.5 ± 0.0 ^ # 19.0 ± 0.8 ^ # 2.6 ± 0.1 ^ 62.8 ± 2.1 # 72.9 ± 3.8 # 67.0 ± 1.8
HFD 5.1 ±0.6 ^ * 0.7 ± 0.1 ^ * 24.7 ± 2.2 ^ * 3.3 ± 0.2 ^ 106.0 ± 3.4 ^ * 85.7 ± 3.3 ^ * 81.0 ± 4.3 ^
* vs LFD
# vs HFD
^ vs YOUNG
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triglyceride hydrolysis.  I used a glycerol assay kit from purchased from Sigma 
(Sigma F6428, G7793).  
 
Figure D1. Lipolysis assay on plasma of YOUNG, LFD, and HFD rats. 
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